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Abstract
Early detection of cancer is believed as one of the best solutions to improve the therapeutic
outcomes and overall survival of cancer patients. Analysis of circulating nucleic acids in bodily
fluids, referred to as “liquid biopsies”, is rapidly gaining prominence for this purpose. Cell-free
DNA (cfDNA) methylation has emerged as a promising biomarker for early cancer detection,
tumor type classification, and treatment response monitoring. Currently, most cfDNA methylation
profiling technologies are based on bisulfite conversion, while enrichment-based methods such as
cfMeDIP-seq are beginning to show potential. To expand the use of enrichment-based methods in
cfDNA methylation profiling, here, we report an ultra-low input method based on methyl-CpG
binding proteins capture, termed cfMBD-seq. We optimized the conditions of cfMBD capture by
adjusting the amount of MethylCap protein along with using methylated filler DNA. Our data
showed high genome-wide correlation between cfMBD-seq with 1 ng input and the standard
MBD-seq (>1000 ng input). Compared with the most commonly used HM450K assay, our results
showed that cfMBD-seq reliably detected 94% of the methylated CpG islands detected by
HM450K, while correctly classifying 98% of non-methylated sites (AUC=0.995). We also found
that cfMBD-seq outperforms cfMeDIP-seq in the enrichment of high-CpG-density regions such
as CpG islands, which play an important role in the regulation of normal biological functions and
diseases. To identify the clinical feasibility of cfMBD-seq, we applied cfMBD-seq to profile the
cfDNA methylome using plasma samples from colorectal (N=13), lung (N=12), pancreatic (N=12)
cancer patients, and non-cancer controls (N=16). We identified 1759, 1783, and 1548 differentially
hypermethylated CpG islands (DMCGIs) in lung, colorectal, and pancreatic cancer patients,
respectively. Interestingly, the vast majority of DMCGIs were overlapped with aberrant

v

methylation changes in the corresponding primary tumor tissues, indicating that DMCGIs detected
by cfMBD-seq were mainly driven by tumor-specific DNA methylation patterns. From the
overlapping DMCGIs, we carried out machine learning analyses and identified a set of
discriminating methylation signatures that had robust performance in cancer detection and
classification. Overall, our study demonstrates that cfMBD-seq is a powerful tool for sensitive
detection of tumor-derived epigenomic signals in cfDNA. Our findings will help to expand on
existing blood-based molecular diagnostic tests and identify novel methylation biomarkers for
early cancer detection and classification.

vi

Chapter 1: Overview of cell-free DNA methylation analysis (Literature review)
Parts of this section were previously published by Cancers, a peer-reviewed, open access journal
of oncology, published semimonthly online by MDPI.
[1] Huang, J.; Wang, L. Cell-Free DNA Methylation Profiling Analysis - Technologies and
Bioinformatics. Cancers (Basel) 2019, 11, doi:10.3390/cancers11111741.
1.1 Background
1.1.1 Early cancer detection
Cancer is one of the leading causes of death worldwide and the total number of diagnosed cancer
cases keeps increasing globally [2]. The dismal mortality rates seen in patients with these
malignancies are associated with advanced stage at the time of diagnosis. To improve the
therapeutic outcomes and overall survival of this patient population, detection of cancer at an early
stage is believed as one of the best solutions. Existing clinical interventions can be more effective
for pre-invasive tumors before clinical symptoms appear. Medical interventions such as surgical
resection are curative for most types of localized cancers that have not metastasized [2]. Successful
examples of early cancer detection including mammography, Pap smear, colonoscopy/fecal test,
and low-dose chest computed tomography have helped reduce the mortality of breast, cervical,
colorectal, and lung cancer, respectively [3-6]. Despite these successes, recommendations for
cancer screening in general populations continue to be debated due to the unacceptably high false
positive rates of existing tests and potential overdiagnosis of nonlethal cancers. Prostate-specific
antigen test, a widely used blood biomarker test for prostate cancer, is an example of the potential
consequences of high false positives and unnecessary medical interventions [7,8]. As a result, most
screening tests have limited ability to detect cancers in the general populations because they are
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only practical when they are used to test individuals who have a high risk of developing the
screened cancer. To overcome these limitations, several efforts have been made towards the
investigation of novel assays that enable early cancer detection with high accuracy. Among those,
the use of liquid biopsies is rapidly gaining prominence for minimally invasive cancer detection
and management [9-11].
1.1.2 Liquid biopsies
Tissue biopsies are the gold standards for the histological diagnosis and molecular characterization
of cancers. However, these conventional sampling methods have shown limitations including the
difficulty in obtaining biomaterial, sampling bias arising from tumor genetic heterogeneity, and
even procedural complications [9]. Liquid biopsies, the minimally invasive sampling and analysis
of analytes from blood or other body fluids, have emerged as a critical supplement to the tissue
biopsies. Liquid biopsy analytes include circulating nucleic acids (cell-free DNA (cfDNA) as well
as cell-free RNAs), circulating tumor cells (CTCs), extracellular vesicles, tumor-educated platelets,
proteins, and metabolites. Since tumor-specific analytes can originate from different tissues,
including metastatic tumor sites, liquid biopsies may represent a whole picture of a patient’s
malignancy and mitigate the problem of tumor heterogeneity [12,13]. Early on, liquid biopsies were
focus on the genomic analyses such as somatic mutations and copy number alterations in CTCs or
cfDNA [14]. Recently, more attentions have been paid to the transcriptome [15], the epigenome
[16,17], the proteome [18], and the metabolome [19]. Moreover, novel artificial-intelligence-based

bioinformatics methodologies are moving the liquid biopsy field towards multiparametric and
multi-omic analyses [20]. Many studies have shown that liquid biopsies have the potential to
provide information about primary tumors or metastases that are meaningful for early cancer
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detection, minimal residual disease monitoring, treatment selection, and response prediction
[10,21,22].

1.1.3 Cell-free DNA
cfDNA in body fluids is a mixture of extracellular DNA fragments that are released from cells via
apoptosis, necrosis, and active secretion [23]. The length of cfDNA is about 167 bp, corresponding
to the unit size of a nucleosome (~147 bp) plus linker DNA associated with histone H1 [24,25].
cfDNA in the circulation has a short half-life between 16 minutes and 2.5 hours, enabling liquid
biopsies as real-time and dynamic monitoring tools for the estimation of tumor burden [26]. A
significantly higher level of cfDNA in cancer patients than in healthy individuals has been reported
[26]. In addition, the increased cfDNA can decrease to a background level following surgery [27].

Results from these studies suggest that tumor cells-derived cfDNA is present in the blood of cancer
patients. This tumor-derived cfDNA is called circulating tumor DNA (ctDNA). The concentration
of ctDNA in plasma has been shown to correlate with tumor size and stage [28]. This association
suggests the prognostic and predictive utility of ctDNA. Patients with detectable ctDNA have
worse survival outcomes than those without [29,30]. Additionally, ctDNA has been found to be a
significantly better prognostic predictor than commonly used tumor markers. Specifically, a higher
level of ctDNA correlates with poorer clinical and radiological outcomes [31,32].
In addition to prognosis and prediction, several studies have demonstrated the potential of cfDNA
in noninvasive early diagnosis of cancer. For example, mutations in cfDNA have been detected in
plasma up to 2 years before cancer diagnosis [33]. However, genomic analysis of cfDNA in earlystage cancer is very challenging because cfDNA is often limited in yield and highly fragmented
[34]. More importantly, ctDNA is extremely underrepresented in the high background of normal

cfDNA [34]. The increasing availability and reliability of highly sensitive technologies, such as
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digital PCR (dPCR) and next-generation sequencing (NGS), are facilitating the detection of the
trace amount of ctDNA in early-stage cancer [35]. Currently, cfDNA-based approaches that focus
on the detection of cancer-associated single-nucleotide variants (SNVs) and somatic copy number
variants (CNVs) have been applied into clinical settings [36]. However, SNV assays have
limitations associated with confounding signals from blood cells due to clonal hematopoiesis [37].
Similarly, CNV assays are limited by minor differences between cases and controls resulting in a
need for increased sequencing depths, which translates into higher costs [38]. More importantly,
these genomic variations have not yet demonstrated robust tissue of origin classification across a
broad range of tumor types. In contrast, given the inherited ability of tracing tissue of origin,
cfDNA methylation has become a promising biomarker in liquid biopsies. Therefore, detection of
tumor-specific cfDNA methylation signatures is believed to be a more robust approach for early
cancer diagnosis.
1.1.4 DNA Methylation
Cancer is defined by not only extensive genetic changes but also additional biological processes
such as the immune microenvironment and epigenetics [39]. Epigenetics include any process that
guides genomic function and activity without altering the DNA sequence [40]. DNA methylation
is a common epigenetic modification that plays an important role in eukaryotes that has important
implications for normal biological functions and diseases. De novo DNA methylation is achieved
by adding a methyl group to the fifth carbon of cytosine (5-methylcytosine, 5mC) via DNA
methyltransferases (DNMTs) (Figure 1). This modification occurs most frequently at cytosine
residues in the sequence context of 5'-C-phosphate-G-3' (CpG) [41]. When located at gene
promoters, DNA methylation is a repressive mark of gene expression. DNA methylation can also
occur at the gene bodies of actively transcribed genes, which enhances gene expression [42]. The
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current human genome build contains about 28 million CpGs, 60–80% of which are methylated
[43]. In the mammalian genome, the majority of CpGs are methylated, except for CpG-rich regions

called CpG islands (CGIs) and the nearby CpG shores (the region within 2 kb of the islands) [44].
On the contrary, the cancer methylome is characterized by global hypomethylation and CpG
islands-specific hypermethylation [45,46]. Genome-wide DNA hypomethylation occurs
predominantly at repetitive regions and causes chromosomal instability [47]. Hypermethylation in
cancer cells is frequently observed in the transcriptional regulatory elements (promoters and
enhancers) of tumor suppressor genes [48]. Beyond that, it has been reported that gene body DNA
hypermethylation can activate the expression of oncogenes such as Homeobox genes [49]. These
methylation aberrations can synergize with driver mutations to facilitate cancer development [50].
Growing evidence suggests that aberrant DNA methylation contributes to the tumorigenesis and
tumor progression [51-54].
The detection of ctDNA methylation aberrations holds great promise as a blood-based test for
cancer diagnosis for several reasons: First, aberrant DNA methylation occurs early during
tumorigenesis and is abundantly present in the entire cancer process [55]. Second, in contrast to the
highly heterogeneous nature of gene mutations, tumors of the same histological type tend to exhibit
similar DNA methylation changes among different individuals [56]. Third, circulating components
are shed from multiple body sites, while the methylation patterns of cfDNA are consistent with the
tissues where they originated from [57]. All these advantages imply that cfDNA methylation may
serve as feasible and reliable cancer biomarkers [58,59]. cfDNA methylation may be combined with
traditional screening in primary diagnosis, choice of therapy, response to therapy prediction,
minimal residual disease monitoring, and recurrence detection for better patient outcomes [60]. In
this chapter, the technologies for DNA methylation analysis were summarized and their
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feasibilities for liquid biopsy applications were discussed. A brief overview of the bioinformatic
approaches for the analysis of DNA methylation sequencing data were also provided. Overall, this
chapter provides informative guidance for the selection of experimental and computational
methods in cfDNA methylation-based studies.
1.2 Technologies for DNA methylation detection
1.2.1 Restriction enzyme-based methods
The use of methylation restriction enzymes (MREs) to cleave DNA at a specific nucleotide
sequence is a classical method for methylation study. A pair of isoschizomers that recognizes the
same sequence and cleavage point but exhibits different sensitivity toward the methylation state is
used in these methods. Methylation-sensitive enzymes cleave only unmethylated DNA and leave
the methylated DNA intact, while methylation-insensitive enzymes can cleave regardless the
methylation status of the recognition sites (see Reference [61] for all available MREs). Based on
this principle, array hybridization assays such as HpaII-tiny fragment enrichment by ligationmediated PCR (HELP) [62], comprehensive high-throughput arrays for relative methylation
(CHARM) [63], and methyl-sensitive cut counting (MSCC) [42] have been developed for DNA
methylation analysis. More recently, MRE digestion has been coupled with sequencing
technologies (MRE-seq) to study the role of DNA methylation in regulating alternative promoters
[64,65]. After MRE digestion, the resulting DNA fragments are directly used for library preparation

and sequencing. The sequencing results reveal the locations of the methylated CpG sites
(undigested sites) within the enzyme recognition sequences and allows the estimation of relative
DNA methylation levels. However, due to the limited CpG-containing recognition sites in
intergenic and distal regulatory elements, MRE-seq tend to exhibit low coverage toward the whole
methylome. Importantly, the severely fragmented nature of cfDNA restricts the application of
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MRE-seq for cfDNA methylation profiling as some restriction sites may have been destroyed. To
address this issue, methylated DNA sequencing (MeD-seq), which takes advantages of the LpnPI
restriction enzyme, has been developed [66]. Unlike other methylation-sensitive enzymes, LpnPI
has less specific recognition sites and its activity is limited by a short template size. Therefore,
LpnPI is suitable for detecting DNA methylation in both CpG-dense and CpG-poor regions. MeDseq has been applied for cfDNA methylation profiling and showed great potential in the discovery
of novel methylation signatures and disease load monitoring [67].
1.2.2 Bisulfite conversion-based methods
Bisulfite conversion-based methods are ideal for the detection of DNA methylation because they
provide qualitative and quantitative information for methylation sites at single base-pair resolution.
Upon sodium bisulfite treatment on denatured DNA, unmethylated cytosine (C) residues are
deaminated to uracil (U) and eventually converted to thymine (T) via DNA amplification, while
methylated C residues remain unchanged during the conversion process (Figure 1) [68]. Analysis
of bisulfite-converted DNA was previously coupled with Sanger sequencing and microarray for
the investigation of specific DNA sequences. Nowadays, by integrating high-throughput nextgeneration sequencing (NGS), the entire methylome can be profiled in a single testing. However,
bisulfite conversion causes substantial DNA degradation [69], which may result in loss of some
critical information, especially for generally very trace amounts of cfDNA. Therefore, the library
preparation and bisulfite treatment process should be optimized before implementation of bisulfite
sequencing into cfDNA study. The key optimization is to perform end repair and methylated
adapter ligation before bisulfite treatment, as this ensures the amplification of pre-ligated cfDNA
(Figure 2). Other technical improvements include library preparation within a single tube and the
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employment of Dynabeads for purification and size-selection. The main bisulfite conversion-based
technologies are summarized below.
1.2.2.1 Whole-genome bisulfite sequencing (WGBS)
WGBS presents as the most comprehensive and informative DNA methylation profiling
technology [70]. The first human genome-wide, single-base-resolution DNA methylation profile
was mapped by WGBS [71]. The major advantage of WGBS is that the methylation state of all
cytosines, including low CpG density regions and non-CpG sites (CpA, CpT, and CpC), can be
detected. However, since the whole methylome is targeted, WGBS is expensive when producing
high depth data. To address the increasing demands for low DNA input, optimized methods such
as single-cell bisulfite sequencing (scBS-seq) [72] and single-cell whole-genome bisulfite
sequencing (scWGBS) [73] have been developed. scBS-seq adopts a post-bisulfite adapter tagging
(PBAT) protocol to reduce bisulfite-induced DNA loss and eliminate the need for global
amplification [74]. This highly efficient PCR-free method can generate library starting from 125
pg of DNA and is potentially applicable for cfDNA analyses [75]. On the other hand, scWGBS
uses post-bisulfite single-stranded DNA library preparation [76]. WGBS has been attempted for
mapping cancer-associated cfDNA methylation in metastatic breast cancer [77]. However, as the
cost of large-scale WGBS is prohibitive, a sample pooling approach was adopted. As a result, a
few prominent samples may overshadow the other samples and the complexity of the study is
weakened. Fortunately, the costs of sequencing have continuously decreased in recent years,
making WGBS more economically feasible. Most importantly, a large-scale WGBS study has been
performed using cfDNA of 1493 cancer patients across more than fifty cancer types and 1135 noncancer controls by the Circulating Cell-free Genome Atlas (CCGA) project [78]. More than
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1000000 CpG sites of interest have been identified by this study and a target panel has been
designed for further investigation using targeted bisulfite sequencing in other cohorts.
1.2.2.2 Reduced-representation bisulfite sequencing (RRBS)
To investigate the methylome more cost-effectively, RRBS was developed by integrating MspI
digestion, bisulfite conversion, and NGS [79,80]. This method preferentially enriches CpG-rich
regions and can detect more than 83% of CGIs in mammalian genome [81]. To apply this method
for limited cfDNA, single-cell RRBS (scRRBS) has been developed and the input is significantly
decreased [82]. To avoid DNA loss, scRRBS integrates all the key RRBS reactions into a singletube reaction so that DNA purification does not occur until the entire procedure is completed
(Figure 2). This is achieved by modifying the buffer system and the reaction volumes to preserve
the activities of different enzymes [83]. Capitalizing on these strategies, RRBS has been
successfully used for methylation profiling of plasma cfDNA for the first time. Consequently,
methylated haplotype analysis in plasma cfDNA has demonstrated the quantitative estimation of
tumor load and tissue-of-origin mapping [84]. Methylation patterns identified by RRBS have
shown 81.6% accuracy (49 out of 60 patients) in minimally invasive classification of pediatric
solid tumors [85]. Like MRE-seq, RRBS has a relatively low coverage toward intergenic and distal
regulatory elements because of the limited CpG-containing recognition sites.
1.2.2.3 Methylated CpG tandems amplification and sequencing (MCTA-seq)
MCTA-seq is a sensitive technique for detecting hypermethylated CGIs [86]. In this approach, a
primer that consists of a semi-random sequence, a unique molecular identifier sequence, and an
anchor sequence is used to amplify the bisulfite converted DNA at the 3’-end. Then, the methylated
CpG tandem sites are selectively amplified using another primer containing the CpG tandem
sequence CGCGCGG. Only fragments with methylated CpG can be further amplified and
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sequenced (Figure 2). This approach allows as little as 7.5 pg cfDNA input achieved by multiple
rounds of amplification. Application of the MCTA-seq in cfDNA has identified dozens of DNA
hypermethylation markers for effective detection of hepatocellular carcinoma [86], colorectal
cancer [87], and gastric cancer [88].

MCTA-seq has also identified 146 tissue-specific

hypermethylation markers that revealed the tissue of origin of cfDNA in liver and pancreas disease
patients [89]. These biomarkers, including known and novel, demonstrated a high sensitivity and
specificity for disease detection. However, since MCTA-seq targets CGCGCGG-rich CpG sites
and preferentially enriches high CpG density regions, it can miss some important methylation
signals in low CpG density regions.
1.2.2.4 Targeted bisulfite sequencing
Although allowing for the discovery of novel DNA methylation alterations, the methods discussed
above is not practical in clinical settings, where a rapid turn-around time, cost-efficient methods
and high depth of sequencing coverage are required [90]. A better way is to focus on specific
regions of interest using target enrichment strategies. Consequently, targeted bisulfite sequencing
is more clinically pragmatic because it is scalable, economical, and allows for a higher sequencing
depth. Depending on target enrichment manners, targeted bisulfite sequencing may be categorized
into the following two groups: amplicon-based enrichment and hybrid capture enrichment (Figure
2). The former uses specific PCR primers to amplify regions of interest after the bisulfite treatment,
such as EFC#93 primers for disseminated breast cancer [91], or Vimentin and Fibulin 1 primers for
hepatocellular carcinoma [92]. The latter is performed in solution using biotinylated oligos such as
probes to capture complementary sequences from the bisulfite converted library. Namely, 5’biotinylated capture probes are used to specifically pull-down DNA fragments that contain target
CpG sites. A comprehensive methylation sequencing assay targeting 9223 consistently
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hypermethylated CpG sites in plasma cfDNA from 68 patients with advanced cancers and 66 noncancer controls has successfully detected the presence of cancer and classified cancer type with
high accuracy (AUC = 0.969; Sensitivity: 83.8%; Specificity:100%) [93]. Additionally, using a
target panel of 103456 distinct regions (17.2 Mb, 1116720 CpG sites) identified from WGBS, the
CCGA project assessed the performance of cfDNA methylation signatures in the detection and
localization of multiple cancer types across all stages at high specificity (Accuracy: 93%;
Sensitivity: 55.2%; Specificity: 99.3%) [78]. Although targeted bisulfite sequencing has been
investigated to have high clinical value, this method is constrained by the relatively complicated
primer and probe design procedures, especially for bisulfite-converted sites.
1.2.2.5 Methylation array
Illumina Infinium HumanMethylation450 BeadChip (HM450K) contains predesigned probes for
more than 450k methylation sites that cover 96% of the CGIs [94] and dominated as the method of
choice for the cancer methylome studies before the prevalence of NGS [95]. Infinium
MethylationEPIC BeadChip (HM850K), a further developed version, covers more than 850k CpG
methylation sites, including almost all sites on the HM450K plus additional CpG sites in the
enhancer regions [96]. Currently, a huge number of HM450K datasets have been archived on the
Gene Expression Omnibus (GEO) [97] and The Cancer Genome Atlas (TCGA) [98]. They have
become outstanding public resources for the discovery of novel DNA methylation markers [99,100]
and the validation of new established DNA methylation assays [101]. As for liquid biopsies, the
Infinium methylation array has been applied for the discovery of methylation biomarkers for
colorectal cancer [102], hepatocellular carcinoma [103] and prostate cancer [104]. The methylation
data have also been used for the deconvolution of the plasma methylome for the inference of tissue
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origins of cfDNA [57]. However, all array-based methods have a drawback in poor genome-wide
coverage of all CpG sites, resulting in the loss of methylation contexts.
1.2.2.6 Methylation-specific PCR (MSP)
MSP is based on the use of two distinct methylation-specific primer sets to detect the DNA of
interest. The methylated primers can amplify both bisulfite-converted methylated DNA and
untreated DNA, while the unmethylated primers are only specific for bisulfite-converted
unmethylated DNA [105]. Taking advantage of real-time PCR, several quantitative MSP (qMSP)
protocols [106-108] and methylation-sensitive high-resolution melting analysis (MS-HRM) [109]
has been developed for DNA methylation analyses. These technologies have been widely used in
the identification and validation of aberrant DNA methylation in cfDNA in breast cancer [110-112],
pancreatic cancer [113], ovarian cancer [114], cholangiocarcinoma [115], hepatocellular carcinoma
[116,117], prostate cancer [118], and lung cancer [119,120]. With the emergence of dPCR, digital

methylation-specific PCR (dMSP) has also been developed for the screening and validation of
cfDNA-based methylation biomarkers for breast cancer [121], prostate cancer [122], and colorectal
cancer [123-125]. Yet, these individual markers only provided a limited picture of the whole tumor
methylome. Therefore, a combination of multiple markers is highly recommended in the clinical
settings to solve the problem of tumor heterogeneity and to ensure a high sensitivity and specificity.
1.2.2.7 Oxidative bisulfite conversion
Ten-eleven translocation (TET) enzymes can oxidize 5mC to 5-hydroxymethylcytosine (5hmC),
5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), which is known as DNA demethylation
(Figure 1) [126,127]. Taking advantage of the fact that cytosines in 5fC and 5caC are not protected
from deamination by sodium bisulfite (Figure 1), oxidative bisulfite sequencing (OxBS-seq) [128]
and TET-assisted bisulfite sequencing (TAB-seq) [129] have been developed, respectively.
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However, as longer bisulfite treatment and oxidative environment are needed for the efficient
conversion of 5mC to 5fC or 5caC, more DNA degradation and DNA damage may occur [130].
Application of these methods in liquid biopsies need further investigation.
1.2.3 Enrichment-based methods
Enrichment-based methods are based on the use of antibodies or proteins to pull-down the
methylated genomic regions for subsequent analysis, while the unmethylated fractions are
excluded by stringent washing. Compared to WGBS, enrichment-based methods have not only
shown a similar sensitivity and specificity [131], but also have many other advantages. They are
cost-effective because only the enriched fragments are sequenced, therefore, many indexed
samples can be pooled simultaneously for a single NGS run. Unlike bisulfite conversion-based
methods, the enrichment approaches do not involve cytosine conversion, therefore keep DNA
sequences intact. Furthermore, they can discriminate 5mC from 5hmC due to the protein-binding
specificity. However, these methods have a relatively low resolution (100-300 bp), and therefore
could not discriminate the exact methylation state of a single CpG site. Additionally, these methods
tend to exhibit biases toward hypermethylated regions. As the standard protocol of these methods
require relatively large amount of DNA input, further optimizations in the library preparation and
methylation enrichment are needed to apply them in cfDNA-based studies.
1.2.3.1 Methylated DNA immunoprecipitation sequencing (MeDIP-seq)
MeDIP was originally developed as an approach for the immunoprecipitation of methylated DNA
followed by a microarray analysis [132]. A low DNA input protocol has been reported to reduce
the required input from 5000 ng to 50 ng DNA. However, using less than 50 ng DNA as an input
was not recommended due to insufficient methylation enrichment [133]. To apply MeDIP-seq for
low-input cfDNA in liquid biopsies, cell-free methylated DNA immunoprecipitation and high-
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throughput sequencing (cfMeDIP-seq) has been developed, where exogenous lambda DNA is used
as a filler to increase the initial DNA input (Figure 3) [134]. The filler DNA ensures a constant
antibody/DNA ratio and helps maintain a similar immunoprecipitation efficiency across different
samples with different cfDNA yields, while minimizing non-specific binding and DNA loss [135].
With the help of filler DNA, the starting cfDNA can be reduced to 1-10 ng. Because the lambda
DNA does not have sequencing adapters, and hence no subsequent amplification, the use of filler
DNA would not interfere with the analysis of sequencing data. cfMeDIP-seq has shown high
accuracy in the classification of a wide variety of cancer types [126]. cfMeDIP-seq has been
applied in plasma cfDNA in renal cell carcinoma patients and the identified classifier performed
accurate classification of patients across all stages [136]. Compared to cfDNA variant analysis,
cfMeDIP-seq is significantly more sensitive for the detection of renal cell carcinoma [137]. The
methylome profiled by cfMeDIP-seq revealed highly specific methylation signatures to detect and
accurately discriminate common primary intracranial tumors that share cell-of-origin lineages [138].
1.2.3.2 Methyl-CpG binding domain protein capture sequencing (MBD-seq)
Instead of immunoprecipitation, the methyl-CpG binding domain (MBD) of methyl-CpG binding
proteins (MBD2 or MECP2) can be used to pull down methylated DNA fragments with the help
of magnetic beads [139]. It has been shown that MBD-based enrichment outperforms MeDIP in
regions with a higher CpG density and identifies the greatest proportion of CGIs [140]. Therefore,
integrating MBD-seq with liquid biopsies may facilitate the discovery of CGIs-specific
hypermethylation signatures. A study has described a low DNA input MBD-seq protocol by
adjusting the DNA to beads ratio and using more incubation time and more stringent wash
conditions [141]. Using this protocol, MBD-seq with a 15 ng DNA input detected 93% of the
methylated loci that were reliably detected using WGBS (sensitivity) at similar levels of the false
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positive rate (specificity). Even with as little as 5 ng DNA, MBD-seq had a 90% of sensitivity and
equal levels of specificity relative to WGBS [141]. Therefore, this low-input technology may be
suitable for liquid biopsy studies. Also, it is expected that the use of exogenous DNA as a filler to
increase the initial input might increase the capture efficiency of MBD proteins as it does for
immunoprecipitation.
1.2.3.3 5-hydroxymethylation profiling
Emerging evidence indicates that 5hmC not only acts as a relatively stable epigenetic marker in
mammals [142] but also correlate with tumorigenesis and tumor progression [143]. Previously,
studies have shown the reduced global 5hmC levels but increased regional 5hmC levels in various
cancer tissues [144]. These observations suggest that 5hmC signatures may also be promising
biomarkers for cancer diagnosis and prognosis. To profile hydroxymethylation in the trace amount
of cfDNA, 5hmC-Seal (aka hMe-Seal) has been developed [145]. In 5hmC-Seal, an azide-modified
glucose is first introduced by β-glucosyltransferase (β-GT) and subsequently biotinylated via click
chemistry in selective chemical labeling (Figure 3). The biotinylated 5hmC is then enriched using
streptavidin beads followed by NGS to determine the genomic distribution of 5hmC, where spikein probes are adopted to test the 5hmC capture efficiency during the 5hmC-Seal assay. The proofof-principle global analysis of hydroxymethylome in cfDNA has been reported [146]. Since then,
the 5hmC-Seal has been used to identify a genome-wide pattern of cancer-associated 5hmC
changes and tissue origins of such changes in plasma cfDNA from a patient-derived xenograft
mouse model [147]. The method has also been used to detect aberrant 5hmC alternations in both
gene bodies and promoter regions for non-small-cell Lung Cancer [148], colorectal cancer [149],
hepatocellular carcinoma [150], and esophageal cancer [151].
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1.3 Bioinformatics analyses of DNA methylation sequencing data
The general workflow for the bioinformatics analysis of DNA methylation sequencing data
includes data processing and quality control, data visualization, statistical analysis (identification
of differential methylation between different groups), and data interpretation. Below, the analysis
strategies for DNA methylation sequencing data are provided. All these strategies are highly
compatible when cfDNA is used as a starting material.
1.3.1 Quality controls and alignment
Before alignment, it is highly recommended to perform some quality control checks to ensure that
the raw data is in high quality. FastQC can provide a QC report which can spot problems that
originate either from the starting library material or from the sequencer [152]. Trimming tools such
as Trimmomatic [153], Trim Galore [154] can be used to trimmed off the low-quality base calls and
sequencing adapter from the 3' end of the reads. For faster data processing, fastp, an all-in-one
FASTQ preprocessor, is recommended. fastp can perform quality control, adapter trimming,
quality filtering, and per-read quality pruning with a single scan of the FASTQ data and it is 2–5
times faster than other FASTQ preprocessing tools [155].
Alignment of bisulfite sequencing data is challenging because the bisulfite converted DNA does
not align to the reference genome. To address this issue, two algorithms have been developed: wild
card algorithm (BSMAP [156], RRBSMAP [157], Pash [158], and GSNAP [159]) and three-letter
algorithm (Bismark [160], BS Seeker 3 [161], and BRAT-BW [162]). The wild card algorithm allows
both Cs and Ts in reads to map into Cs in the reference genome, while the three-letter algorithm
converts all Cs in the reference genome and the reads into Ts, and thus standard aligners can be
adopted [163]. Post-alignment quality control is important for bisulfite sequencing data to reliably
quantify read counts and the methylation level per base. For example, base-calling quality should
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be checked because miscalled bases can be counted as C-T conversions. Since the end repair step
in library preparation may introduce either methylated or unmethylated Cs [164], low quality bases
on sequence ends should be trimmed to minimize false C-T conversions. It is also critical to check
the unique alignment rates and insert lengths after trimming because bisulfite treatment can cause
substantial DNA degradation. Incomplete bisulfite conversion may cause false positive results as
unconverted unmethylated Cs are considered as methylated. To address this issue, spike-in
sequences are usually added to measure the bisulfite conversion rate. As the majority of CpGs with
high inter-population differences contain common single nucleotide polymorphisms (SNPs) [165],
filtering out known C/T SNPs is highly recommended. Additionally, removal of duplicate reads
that align to the same genomic position arising from PCR amplification should be considered.
However, this is problematic in RRBS because by design reads start at the same position even if
they are not PCR duplicates. Instead, one can remove regions with unusually high read counts.
Differing from bisulfite-based methods, standard aligner (bowtie2 [166], BWA [167]) can be
directly used for the alignment of enrichment-based sequencing data, because no mutation is
introduced during library preparation. In the cases of enrichment-based sequencing data, none of
the post-alignment quality control issues regarding C-T conversions mentioned above need to be
considered. Duplicate reads are increasingly likely to occur because reads are expected to align to
a smaller methylation-enriched genome, where some duplicate reads occur by chance owing to the
methylation enrichment, not the over-amplification. Poisson statistic has been used to determine
the maximal number of duplicate reads allowed per genomic position [168].
1.3.2 DNA methylation calling
After a series of post-alignment quality control, the methylation level (a number ranging from 0 to
1) of individual CpG site can be calculated in the bisulfite sequencing data. This is simply done
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by counting the number of C-T conversions and dividing the number of Cs by the sum of Cs and
Ts for each C. As a relative ratio, the methylation level would normalize the coverage difference
at each CpG site, which vary dramatically due to genomic feature and amplification differences.
Thus, additional normalization across different samples is not needed for bisulfite sequencing data.
Moreover, the methylation level can be easily fit into many commonly used statistics models for
differential methylation analysis as it is a continuous variable. However, the methylation level
calculated from the CpG site with a low sequencing depth is less reliable.
Unlike bisulfite sequencing data, data from enrichment-based methods are usually analyzed by
comparing the relative abundance of fragments. Generally, the genome is divided into nonoverlapping adjacent windows of a specified width, and the number of reads in each window across
all samples can be used for further analysis. For analysis involving multiple samples, data
normalization is crucial to remove biases between samples or different batches. TPM (transcripts
per million) and RPKM/FPKM (reads/fragments per kilobase of transcript per million reads
mapped) are popular choices as they rescale read counts for differences in both the sequencing
depth and fragment length [169]. However, TPM and RPKM/FPKM normalized data are not
suitable for differential methylation analysis. Because the difference in biological methylation
composition is not considered and the few hypermethylated regions between samples can skew the
normalization. Instead, the trimmed mean of M-values (TMM) [170] and DESeq2 [171]
normalization are highly recommended because they not only normalize the sequencing depth but
also account for the methylation composition. They calculate a scaling factor via different
algorithms and then read counts are normalized by the scaling factor. The genomic binning
function and TMM normalization are implemented in the R package MEDIPS [168], while DESeq2
normalization is implemented in the R package DESeq2. More recently, a Bayesian statistical
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model that transforms the methylation enrichment read counts to absolute methylation levels has
been developed and is implemented in the R package QSEA [172,173]. Additionally, a nonparametric method that uses isolated CpGs to estimate sample-specific fragment size distributions
for the estimation of the methylation level of each CpG site has also been developed and is
implemented in the R package RAMWAS [174,175].
While normalization is essential before differential expression analyses, visualization of data is
also necessary whenever read counts between samples are compared. UCSC Genome Browser [176]
and Integrative Genomics Viewer (IGV) [177] are usually used for data visualization. Methylation
plotter [178] and Web Service for Bisulfite Sequencing Data Analysis (WBSA) [179] are specially
designed for visualization DNA methylation sequencing data.
1.3.3 Determination of differential methylation
Following methylation calling, statistical tests can be employed to identify differential methylation
between cases and controls. Differential methylation in cancer means CpG sites or regions that
have different DNA methylation patterns between cancer patients and healthy individuals. For a
comparative analysis of the methylation level (from 0 to 1) on a CpG site or region between
multiple samples, statistical methods such as t-test, ANOVA, and nonparametric test (Mann–
Whitney U test and Kruskal-Wallis test) may be used. T-test is used to examine if two sets of
samples have significantly different means (R package BSmooth [180] and Minfi [181]). It is a
parametric test and requires the samples to be independent and normally distributed. ANOVA is
based on linear models for a multiple-group comparison (R package Minfi). Thus, it is more
flexible to incorporate multiple clinical covariates and to accommodate different study designs.
Considering the distribution of methylation level among the study population is unknown,
nonparametric test is a safer approach in methylation studies as it is free of distribution assumption
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(R package limma [182]). The Mann–Whitney U test evaluates if two comparison samples have
identical medians and thus it is less affected by outliers. However, nonparametric test has less
power and will be problematic when the sample size is small.
Bisulfite sequencing data can also be analyzed based on read counts. Read count is the number of
methylated and unmethylated cytosines at a CpG site. Contingency table test (Fisher’s exact or
chi-square test), clustered data analysis [183], logistic regression, and the beta-binomial model [184186] may be used for read counts based analyses. Contingency table test is the simplest method

when replicates are not available, however, it does not take the variability of interindividual
variation into consideration (R package COHCAP [187]). Clustered data analysis is an optimized
version of the contingency table test as it incorporates the between-subject variability. This method
can be considered as performing the chi-square test for independence in a series of contingency
tables. However, large sample size is needed since the test is based on approximation. Logistic
regression is a form of generalized linear model (GLM) for binary data (R package methylKit
[188]). However, there are clearly more biological variability than the binomial assumption (only

methylated and unmethylated) in the data. Regression methods allow adding covariates, such as
age and sex into the tests, which are shown to be influential on the methylation level [189]. Among
these models, the beta-binomial model is the best method for balanced sensitivity and specificity
in differentially methylated cytosines (DMCs) detection (R package methylSig [185]) [190]. For
enrichment-based read count data, well established RNA-seq data analysis R packages such as
DESeq2 [191] and edgeR [192] can be directly applied to the normalized read count matrix for
differential methylation analysis.
As the methylation level between neighboring CpG sites are potentially positively correlated, a
combination of multiple adjacent CpG sites into a defined region called differentially methylated
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regions (DMRs) can reduce the number of hypothesis tests and thereby improve the statistical
power [164]. DMRs can be determined by clustering nearby DMCs. DMRs can also be defined
based on predefined regions, such as gene promoters and CpG islands, or adjacent CpG sites within
user-defined non-overlapping windows across the whole genome [193]. To better measure weak
methylation differences, increasing the biological replicates and sequencing depth present a good
strategy to obtain more robust p-values. The inherent limitation of high dimensional data is false
positive. Therefore, statistical results must be subjected to multiple testing corrections. Among all
options, Bonferroni and false discovery rate (FDR) are the most commonly used multiple testing
correction methods. Comprehensive evaluation of almost all tools and statistical methods for
identifying DMRs for DNA methylation sequencing data has been summarized [190,194-198]. After
the identification of DMRs, the regions of interest often need to be integrated with genome
annotation datasets, which allows for determining whether the DMRs are related to genes and gene
regulatory regions. The R package Genomation [199] and annotatr [200] are good annotation tools.
1.3.4 Identification of tumor-specific methylation profile
Due to the high background of normal cells-derived cfDNA, the ctDNA concentration in cfDNA
is generally low in cancer patients. Therefore, it is challenging to identify ctDNA methylation,
especially in early-stage cancer. One common strategy is to use the methylation profile of tumorfree peripheral blood mononuclear cells (PBMCs) as a negative control. By comparing DMRs
between cancer cfDNA and healthy cfDNA to DMRs between cancer cfDNA and PBMC genomic
DNA, the shared regions are considered to be tumor specific DMRs. This strategy has been applied
in many studies that identified the ctDNA methylation signatures [99,134,146,147]. Additionally, a
reference-based deconvolution algorithm has been developed for correcting cell-type
heterogeneity [201]. This algorithm allows for the recovery of the original signal from a mixture of
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signal sources by using reference datasets. Therefore, it is suitable for the deconvolution of data
from heterogeneous samples like cfDNA, using public available tissue-specific or cancer typespecific methylation data. The deconvolution algorithm has been successfully applied to estimate
ctDNA content and differentiate tissue-of-origin in cfDNA of patients with lung or colorectal
cancer [84]. Recently, probabilistic models have been formulated to identify ctDNA methylation.
CancerLocator, a tool for non-invasive cancer diagnosis and tissue-of-origin prediction, is based
on such a model [202]. By using Infinium HM450K data from TCGA, CancerLocator identified
many CpG cluster features that have significant methylation variation across cancer and normal
samples, as well as modeled methylation levels in different cancer types. Thus, the ctDNA burden
and the likelihood of the presence of a specific cancer type can be inferred based on the informative
CpG clusters. A further developed version, CancerDetector, adopts the joint methylation states of
multiple adjacent CpG sites on an individual sequencing read and jointly deconvolutes the tumor
fraction across all markers, has achieved a high sensitivity and specificity in detecting ctDNA
methylation [203]. The Bayesian hierarchical model and methylation haplotype analysis share a
similar strategy that enables information sharing across a cluster of neighboring CpG sites in order
to enhance the statistical power [84,172,184].
1.4 Current challenges and future directions
In the early years, whole blood (buffy coat) DNA was preferentially used as a starting material for
liquid biopsies. However, the high background of the hematopoietic cell genome may cause a false
positive detection of tumor specific DMRs. Later, plasma was proven to be a superior source of
cfDNA owing to the lower background levels of normal cfDNA [204]. Although superior, the
cfDNA yield and ctDNA fraction are still limited in early-stage cancer plasma samples. To ensure
successful and solid results, most biomarker studies are limited to plasma samples from metastatic
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and late-stage cancer patients. However, biomarkers identified from advanced-stage disease are
not fully applicable for early-stage cancer due to the dramatic methylation changes during disease
progression. That’s why useful methylation signatures have yet not been fully established in
clinical practice although cfDNA methylation profile in cancers has been known for a decade. One
should be aware that if a certain region of DNA is not present in the sample, no target enrichment
technique can retrieve it. Given the extremely low ctDNA content, the early-stage cancer plasma
is expected to contain a low copy number of tumor genome equivalents. Therefore, the region with
low sequencing read counts should be considered as a potential tumor-derived signal.
Unfortunately, most analytical pipelines do not take such a scenario into consideration and filter
out low-depth regions as part of routine quality control. Although most existing computational
data analysis methods are applicable for cfDNA methylation sequencing data, further
improvements in programing are still needed to detect the trace amount of tumor-derived
methylation signal in early-stage cancer.
The use of NGS in epigenetic studies has significantly facilitated the discovery of DNA
methylation biomarkers. However, these studies also face some challenges, including the lack of
a uniform pipeline for both experimental and computational methods. Thus, different laboratories
may identify different set of biomarkers even from the same type of disease or the same set of
samples. In some cases, different researchers may have different interpretations on the same
datasets. To eliminate the inconsistency arising from tumor heterogeneity and distinctive technical
and analytical methodologies, integration of different methylation assays may be considered as a
strategy of choice. It is believed that the combination of various methylation assays will guarantee
the generation of more reliable biomarkers. If a genomic region can be identified by different
methylation assays in different patient cohorts, it will be believed as a robust biomarker. The
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reliability of a novel detection assay can also be validated by existing assays. For example, the
high consistency of methylation profile generated by cfMeDIP-seq was validated by comparing
with traditional MeDIP-seq, RRBS, and WGBS [134]. Additionally, the combination of multiple
methylation signatures will help to achieve a higher accuracy performance in a diagnostic or
prognostic model. For instance, recent studies for the early detection of breast cancer and for the
monitoring of treatment response in colorectal cancer used multiple methylation signatures to
improve model prediction outcome [121,205]. Furthermore, the integration of cfDNA methylation
analysis with other aberrant cfDNA alternations assays, such as copy number variations and point
mutations, will also improve the diagnostic sensitivity and specificity.
Although promising, the integrated strategy will produce more complicated data, which requires a
more sophisticated analytical algorithm. With the rapid development of new computational
technologies, the use of machine learning for diagnostic and therapeutic decision making is
receiving more popularity. For example, artificial intelligence systems have been adopted for
methylation analysis in recent studies [110,134,206]. It is expected that machine learning will allow
for the identification of trends and cancer-specific patterns with ease. However, machine learning
has many obstacles. First, machine learning analysis requires massive training data sets. However,
studies aimed to prove the robustness of cfDNA biomarkers often possess inadequate sample size
and statistical competency. Second, cohort information such as sex, age, cancer type and stage, as
well as diverse preanalytical factors (sample collection and storage) are necessary. However, it is
always difficult to collect comprehensive clinical information for all patients. Third, machine
learning analysis is a complex and time-consuming process. Therefore, adept computer
programing skill as well as statistical knowledge are required for scientists to comprehensively
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analyze and interpret the vast amount of data. Significant efforts are still needed to fully apply
cfDNA methylation signatures for cancer detection and outcome prediction in the clinical settings.
Besides cfDNA methylation, other epigenetic biomarkers have also been explored for liquid
biopsies. With the rapid development of cell sorting technologies, investigation of the methylome
in circulating tumor cells (CTCs) has become possible [207]. A fundamental connection between
phenotypic features of CTCs and DNA methylation dynamics in stemness and metastasis has been
identified recently [208]. More knowledge regarding the CTC methylome remains to be further
explored. Meanwhile, cell-free RNA methylation and cfDNA fragmentation patterns also deserve
more research attentions in the future [209,210].
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Figure 1. The dynamic regulation of DNA methylation
Cytosine variants and their products by bisulfite conversion. DNA methyltransferases (DNMTs)
convert unmodified cytosine (C) to 5-methylcytosine (5mC) by adding a methyl group. Ten-eleven
translocation (TET) enzymes oxidize 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine
(5fC) and 5-carboxylcytosine (5caC). Thymine DNA glycosylase (TDG) and the base excision
repair (BER) pathway allow for regeneration of C from 5fC and 5caC. Upon bisulfite treatment,
unmethylated cytosine (C) is deaminated to uracil (U) and eventually converted to thymine (T) via
DNA amplification, while methylated C remains unaffected. 5hmC also protects C from
deamination, while 5fC and 5caC do not.
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Figure 2. Schematic diagram of bisulfite-based methylation profiling technologies
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Figure 3. Schematic diagram of enrichment-based methylation profiling technologies
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Figure 4. Computational pipeline for DNA methylation sequencing data analysis
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Table 1. Strengths and weaknesses of all major methylation assays for liquid biopsies
Class

Technology

Restriction
enzyme-based

Strength

Weakness
Cost
-Low resolution
-Limited to regions in proximity to restriction
enzyme sites

-High CGI coverage
qPCR or dPCR

Bisulfitebased

-Allows ultra-low DNA input
-Easy primer design

-Loci-specific studies only

-Single-based resolution

-Substantial DNA degradation during bisulfite
treatment
-Cannot discriminate between 5mC and 5hmC

-The most comprehensive profiling
-Relatively low sequencing depth
of the whole methylome
-Limited to regions in proximity to restriction
RRBS
-High CGIs coverage
enzyme sites
-Limited to CGIs and might decrease other
MTCA-seq
-High CGIs coverage
methylation backgrounds
-Detect target CpG sites at high
Targeted
-Complicated primer or probe design
coverage
-Pre-designed panel covering
Microarray
-Low genome-wide coverage of CpGs
hotspot methylation
-Loci-specific studies only
qMSP or ddMSP -Allows ultra-low DNA input
-Complicated primer or probe design
-Low resolution
-No mutation introduced
-Biased toward hypermethylated regions
-Less sensitive in regions with high CpG
MeDIP-seq
-Antibody is specific to 5mC
density than MBD-seq
-High sequencing depth is required as 5hmC
-Specific to 5hmC
has a low abundance
-Ensures accurate capture of DNA
5hmC-Seal
-Low resolution
containing 5hmC
-Oxidative environment would cause DNA
hmC-CATCH
-Single-based resolution
damage
WGBS

Enrichmentbased
5hmC
profiling
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Low

High
Moderate
Moderate
Low
Low
Low

Moderate

Moderate
Moderate

Chapter 2: Optimization of MBD-seq for low input cell free DNA methylome profiling
Parts of this section have been accepted for publication in Epigenetics, published by Taylor &
Francis.
[101] Huang, J.; Soupir, A.C.; Wang, L. Cell-free DNA methylome profiling by MBD-seq with

ultra-low input. Epigenetics 2021, 1-14, doi:10.1080/15592294.2021.1896984.
2.1 Introduction
Currently, the majority of cell-free DNA (cfDNA) methylation profiling technologies are based
on chemical treatment of the DNA with bisulfite [1]. Although whole-genome bisulfite sequencing
(WGBS) of cfDNA has been attempted, this approach is not feasible for most clinical studies
because of prohibitive cost and limited information recovery owing to the low genome-wide
abundance of CpGs [211,212]. To address this issue, highly sensitive targeted assays such as
targeted bisulfite sequencing and digital methylation-specific PCR have been developed [78,213].
The scalable and economical targeted bisulfite sequencing has been applied in large-scale cfDNAbased clinical studies [78,93]. High accuracy diagnostic prediction models of hepatocellular
carcinoma and colorectal cancer have been established from a large cohort of patients and healthy
controls [214,215]. However, the target methylation markers of these studies were selected from
Infinium HumanMethylation450 BeadChip (HM450K) data. This methylation array is known to
have selection bias and poor genome-wide coverage of all methylation sites, which may result in
omission of important targets [99]. Similarly, the applications of quantitative and digital
methylation-specific PCR are restricted by their low throughput nature. Alternatively, enrichmentbased methylation profiling methods have shown a similar sensitivity and specificity when
compared to bisulfite conversion-based methods [131]. Methylated DNA can be captured by
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methyl-CpG binding proteins (MBD) or anti-5mC antibodies (MeDIP) that have high affinity
toward methylated CpGs. One critical limitation of such methods for liquid biopsy applications is
that a relatively large amount of input DNA (ideally >1000 ng) is required, while the yield of
cfDNA is typically low (2~10 ng/ml plasma). To address this issue, Shen et al. optimized the
MeDIP-seq protocol to allow methylome analysis of small quantities (1–10 ng) of cfDNA, termed
cfMeDIP-seq [133-135].
Intrigued by the low-input improvements in cfMeDIP-seq, we optimized MBD-seq [139] to enable
as little as 1 ng cfDNA input and termed this ultra-low input protocol cfMBD-seq. We first
optimized the methylation capture reaction in a 100 ng DNA mixture (10 ng cfDNA + 90 ng filler
DNA) by adjusting the amount of MethylCap protein and protein-binding Dynabeads. We then
tested the effect of the methylation status of filler DNA in the methylation enrichment. We also
compared the methylome profile generated by cfMBD-seq across different DNA input (1-100 ng)
with the one generated by standard MBD-seq (1000 ng DNA input). Additionally, we investigated
if using more filler DNA, applying double wash, or using elution buffer with different salt
concentration can further improve the methylation enrichment. To verify if the methylation signals
captured by cfMBD-seq are real, we compared cfMBD-seq with most existing methylation
profiling assays including HM450K, WGBS, reduced representation bisulfite sequencing (RRBS),
and cfMeDIP-seq. All the results we showed below demonstrate that this novel bisulfite-free ultralow input technology is promising in non-invasive, highly sensitive, and cost-effective methylation
profiling.
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2.2 Material and methods
2.2.1 DNA extraction
Pooled human plasma (IPLAWBK3E50ML) was purchased from Innovative Research (Novi, MI,
USA). Whole blood (K3 EDTA tube) was collected from donors in an FDA-approved collection
center. Plasma was frozen immediately after isolation. After thawing, additional centrifugation on
3000 rpm for 10 mins was performed to ensure complete depletion of cell debris. cfDNA was
extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen; Hilden, Germany) and
quantified with a Qubit Fluorometer using the iQuant™ NGS-HS dsDNA Assay Kit (Genecopoeia;
Rockville, MD, USA). The average cfDNA yields from 1 ml plasma was ~7.5 ng. Colorectal
carcinoma cell line HCT116 was purchased from ATCC (CCL-247™) and cultured according to
the recommended cell culture method. HCT116 DNA was extracted using the QIAamp DNA
Blood Mini Kit (Qiagen) and quantified with Nanodrop (NanoDrop Technologies; Wilmington,
Delaware, USA). gDNA was sheared to 160 bp using a Covaris ME220 Focused-Ultrasonicator to
mimic the fragment size of cfDNA. HCT116 was chosen because of the availability of public DNA
methylation data.
2.2.2 Filler DNA generation
To generate filler DNA, Enterobacteria phage λ DNA was polymerase chain reaction (PCR)
amplified with the GoTaq Master Mix (Promega; Madison, WI, USA). Primer sequences are as
follows: Forward primer 5’- CGATGGGTTAATTCGCTCGTTGTGG-3’, reverse primer 5’GCACAACGGAAAGAGCACTG-3’. The 274 bp amplicons were treated with CpG
methyltransferase (M.SssI; Thermo Fisher Scientific) to methylate amplicons. Methylated
amplicons were purified by the DNA Clean & Concentrator-5 Kit (ZYMO Research; Irvine, CA,
USA) and quantified by Qubit Fluorometer. CpG methylation-sensitive restriction enzyme
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HpyCH4IV (New England BioLabs; Ipswitch, MA, USA) digestion followed by agarose gel
electrophoresis was performed to ensure complete methylation of filler DNA.
2.2.3 Library preparation
DNA was subjected to end repair/A-tailing and adapter ligation using the KAPA Hyper Prep Kit
(Kapa Biosystems; Wilmington, MA, USA) with the sequencing adapter from NEBNext Multiplex
Oligos for Illumina (New England BioLabs; Ipswitch, MA, USA). The amount of adapter used in
the reaction was adjusted according to an adapter:insert molar ratio of 200:1. Adapter ligated DNA
were purified with 0.8x SPRI Beads (Beckman Coulter; Pasadena, CA, USA) and digested with
the USER enzyme (New England BioLabs) followed by purification with the DNA Clean &
Concentrator-5 Kit (ZYMO Research; Irvine, CA, USA). Adapter ligated DNA was first combined
with methylated filler DNA to ensure that the total amount of input for methylation enrichment
was 100 ng, which was further mixed with 0.2 ng of methylated and 0.2 ng of unmethylated A.
thaliana DNA from the DNA Methylation control package (Diagenode, Seraing, Belgium).
2.2.4 cfMBD-seq
The DNA mixture was then subjected to methylation enrichment using the MethylCap Kit
(Diagenode) following the manufacture’s protocol with some modifications. The total volume
brought up by Buffer B was reduced from 141.8 μl to 136 μl to minimize DNA waste. The amount
of MethylCap protein and magnetic beads were decreased proportionally according to the
recommended DNA to protein and beads ratio (0.2 μg protein and 3 μl beads per 100 ng DNA
input). Single fraction elution with the High Elution Buffer was applied. The eluted fraction was
purified by the DNA Clean & Concentrator-5 Kit. The purified DNA was divided into two parts,
one for qPCR (PowerUp™ SYBR™ Green Master Mix, Thermo Fisher) quality control, another
for library amplification. The recovery of spiked-in methylated and unmethylated control can be
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calculated based on the cycle threshold (Ct) value of the enriched sample and input control. The
specificity can be calculated by (1 - [recovery of unmethylated control DNA over recovery of
methylated control DNA]) × 100). The methylation-enriched DNA libraries were amplified as
follows: 95 °C for 3 min, followed by 12 cycles of 98 °C for 20 s, 65 °C for 15 s and 72 °C for 30
s and a final extension of 72 °C for 1 min. During the amplification, unique index from primer was
added to the sequencing adapter for each sample. The amplified libraries were purified using 1x
SPRI Beads followed by a dual size selection (0.6x followed by 1.2x) to remove any adapter dimers.
All final libraries were first quantified with both Qubit assay and qPCR-based quantification using
the KAPA Library Quantification Kit (Kapa Biosystems). Then they were submitted to Moffitt
Cancer Center Molecular Genomics Core for the D1000 ScreenTape Assay (Agilent; Santa Clara,
CA, USA). Sequencing was performed on the NextSeq 550 platform (Illumina; San Diego, CA,
USA) with high-output 75 bp single-end read, multiplexed as ~12-15 samples per run. The
sequencing data are available on GEO under accession number GSE161331.
2.2.5 Data processing
After sequencing, pre-alignment quality control was performed for the raw sequenced reads using
fastp (Version 0.20.1) [155] with the default settings. The sequenced reads were then aligned to the
human genome (hg19) using Bowtie-2 (Version 2.4.2) [166] with the default settings. The
generated sam files were converted to bam files, followed by sorting, indexing, duplicate read
removal, and read count extractions on chr1 - chr22 using SAMtools (Version 1.11) [216] ‘sort’,
‘index’, ‘markdup’, and ‘view’ command lines, respectively. R (Version 4.0.3 or greater) package
RaMWAS (Version 1.12.0) [175] was used for quality control of the overall mapping quality and
calculation of average non-CpG/CpG ratio and coverage by CpG density. To ensure the
comparability between different conditions, bam files from the same experimental condition were
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(https://github.com/ACSoupir/MiscProcessingScripts) from each condition for the plotting of
coverage by CpG density plot. R package MEDIPS (Version 1.40.0) [168] was then applied for
saturation analysis and calculation of correlations of genome wide short read counts profiles
between samples based on counts per 1000 bp non-overlapping window. Normalized data were
exported as wiggle files for visualization on the Integrative Genomics Viewer [177].
Genome-wide CpG annotations reference was obtained from R package annotatr (Version 1.16.0).
BEDtools (Version 2.28.0) [217] ‘coverage’ command line was used to call the depth of features
according to the CpG annotations reference. TPM (Transcripts Per Kilobase Million)
normalization was performed before comparing the read counts of CpG annotations regions
between different samples. Data from low-input MBD-seq and cfMeDIP-seq were reprocessed
from raw data (fastq level) using the same workflow. R package minfi (Version 1.36.0) was used
to call and annotate (hg19) methylation signal from Infinium HM450K data. Average beta-values
of each CpG site among different samples was first calculated. Methylation status of CpG islands
was then determined by the average beta-values of adjacent CpG sites within the same CpG island
(<0.5 as unmethylated and ≥0.5 as methylated). Logistic regression model was built using
normalized read counts from cfMBD-seq and methylation status (methylated as 1 and
unmethylated as 0) from microarray. R package ROCR (Version 1.0-11) was used to generate
receiver operating characteristic curve. All data and R images were imported into GraphPad Prism
8 for the preparation of figures. Detailed bioinformatics analysis pipeline was coded in git bash
and is available in GitHub (https://github.com/LiangWangLab/cfMBD-seq).
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2.3 Results
2.3.1 Characterization of cfMBD-seq technology
The standard protocol for MBD methylation enrichment requires a minimum input of 1000ng
DNA. Since the yield of cfDNA is extremely low (2-10 ng per ml plasma), the current protocol is
not suitable for cfDNA methylation analysis. To guarantee amplification of methylation-enriched
cfDNA, we added sequencing adapters to cfDNA by end repair/A-tailing and ligation before the
methylation enrichment. Since newly synthesized DNA are not methylated, library amplification
was not performed until the methylation enrichment is done. To meet the high input requirement
for methylation enrichment, we added exogenous Enterobacteria phage λ DNA (filler DNA) to the
adapter-ligated cfDNA to increase the final DNA input to 100 ng. The filler DNA ensures a
constant MethylCap protein/DNA ratio and helps maintain a similar methylation enrichment
efficiency across different samples with different cfDNA yields, while minimizing non-specific
binding and DNA loss. Since the filler DNA is not adapter ligated, thus it is not amplified and
sequenced, it will not interfere with the analysis of sequencing data. Beside filler DNA, we also
added methylated and unmethylated A. thaliana DNA as spike-in controls to verify the specificity
of methylation enrichment. Unlike genome wide sequencing, cfMBD-seq captures only a fraction
of the genome (methylated DNA) and thus allows adequate sequencing depth from less total reads.
Therefore, it enables pooling of multiple uniquely indexed samples for a single sequencing run.
This makes cfMBD-seq a cost-effective method for methylome-wide association analysis in a
large-scale study (for more details, see Methods and Figure 5a).
2.3.2 Reduced MethyCap protein improves methylation enrichment
Based on the use of filler DNA, we performed extensive benchmarking to identify an optimal
methylation enrichment condition. One of the key adaptions for this purpose is to determine an
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appropriate amount of MethylCap protein to bind the input DNA mixture. If the amount of protein
is too high, non-specific binding will occur due to extra binding sites on the protein. If too low, a
portion of methylated fragments will not be captured. Using a mixture of 10 ng adapter ligated
cfDNA and 90 ng filler DNA as input, we tested across different ratios of MethylCap protein and
magnetic beads to the input DNA. When we kept the same MethylCap protein/DNA ratio as
recommended by the manufacturer’s protocol, where 2 μg MethylCap protein is used for 1 μg
DNA (2:1 ratio), the captured CpG islands reached up to 58.65% of all mapped reads (Figure 6a).
Since methylation differences sometimes occur at a short distance away from the CpG islands [218],
we also calculated the sum of captured reads from CpG islands/shores/shelves regions. Under the
recommended 2:1 ratio, 94.56% of reads were mapped into the extended regions, while these
regions only account for 6.72% of the entire genome (Figure 5b, 6b). We then plotted the genomewide coverage (average number of fragments covering CpGs) against CpG density (number of
CpGs per fragment). The curve showed that the number of sequence reads was relatively low in
CpG-poor regions and ultra-dense regions, while peaks in regions with moderate CpG density. As
the peak represents CpG-rich regions such as CpG islands, the higher coverage at the peak
indicates the better methylation enrichment (Figure 6c). To better characterize these distributions,
we termed the CpG density at the point of the highest coverage as “peak”. We also used the term
“noise” to illustrate the ratio of average non-CpG/CpG coverage. Consistently, the 2:1 ratio gives
the highest peak and the lowest noise values (Figure 6d). Unlike the tremendous impact from
MethylCap protein, the amounts of magnetic beads had less impact on the methylation enrichment.
Given redundant beads may increase the risk of unspecific binding, we determined 0.2 μg protein
and 3 μl beads as the best enrichment condition for 100ng DNA input.
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2.3.3 Methylated filler DNA is needed to increase enrichment efficiency
In MBD methylation enrichment, the typical yields of methylated DNA are 3-20% of the input
DNA mass. Since cfDNA only accounts for a small fraction (<10%) in the mixture of cfDNA and
filler DNA, the tiny amount of methylated cfDNA may not be able to fill all binding sites on the
MethylCap proteins. If the filler DNA is not methylated, the risk of unspecific binding may be
increased. To test the potential impact of filler DNA methylation status on the enrichment
efficiency, we used different methylation status of filler DNA for cfMBD-seq, including: 1.
Treated with CpG methyltransferase; 2. The mixture of the treated and untreated (1:1 ratio); and
3. Untreated. When the filler DNA is methylated, we observed better enrichment of sequence reads
in both the CpG islands and CpG islands/shores/shelves regions. The sequence reads percentage
of these regions were decreased with the reduction of filler DNA methylation level (Figure 7a,7b).
Specifically, the percentage of sequence reads on CpG islands was 58.65%, 40.05%, and 20.53%
when methylation level of filler DNA was 100%, 50%, and 0%, respectively. The extended regions
showed the same trend. The coverage by CpG density plot (Figure 7c) and peak/noise plot (Figure
7d) further showed the importance of fully methylated filler DNA. Since the methylated filler
DNA can block the extra binding sites on the MethylCap protein, it is not difficult to explain why
the specificity of the reaction was enhanced.
2.3.4 Pre-sequencing quality controls
As we empirically found that the library yields from different experiment conditions are different,
we hypothesized that a non-specific methylation capture would generate a higher library yield. To
test this, we examined final library concentration and the quality of methylation enrichment. We
found that the optimal condition tended to have a lower library yield while the suboptimal
conditions generated more final library DNA when under the same PCR amplification cycles
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(Figure 8a, 8b). This can be explained by the high specificity of the optimal methylation
enrichment that only captures methylated DNA. Beside library concentration, real-time PCR
(qPCR) often provides a more accurate pre-sequencing quality control. Since cfDNA is highly
fragmented, the use of large amplicon is not recommended. Thus, the methylated control TSH2B
(170 bp) provided in the kit is not an optimal spike-in control. On the other hand, qPCR has a
limited sensitivity to detect the provided unmethylated control GAPDH in a successful enrichment
due to low input. Therefore, instead of the TSH2B and GAPDH control pair provided in the kit,
we used methylated and unmethylated A. thaliana DNA as spike-in controls to estimate the
enrichment efficiency. We observed a significant enrichment of methylated DNAs when compared
the spike-in controls before and after the capture reaction. Under the optimal condition, the
specificity of capturing methylated control DNA was ≥99%. Additionally, the recovery rate of
the methylated and unmethylated control should be ~50%-90% and <1%, respectively. (Figure 8c,
8d).
2.3.5 1ng input achieved high quality results like 1000ng input DNA
To investigate if the methylome from low-input cfMBD-seq is equivalent to the one from standard
MBD-seq (>1000 ng input), we sheared colorectal cancer cell line HCT116 DNA into small
fragments with a peak of ~167 bp to mimic cfDNA and tested the efficiency of methylation
enrichment across different DNA input (1, 10, 100, and 1000 ng). For 1 ng and 10 ng HCT116
DNA, we used methylated filler DNA to increase the final DNA input to 100 ng and followed the
cfMBD-seq protocol. For 100 ng HCT116 DNA, we directly applied the cfMBD-seq protocol
without filler DNA. For 1000 ng HCT116 DNA, standard MBD-seq protocol was used. Saturation
analysis of sequencing result showed a high saturation correlation across different DNA input
(Figure 9a-d). Specifically, the saturation correlation is 0.91 when the DNA input is only 1 ng,
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indicating that 1 ng DNA is sufficient to generate a saturated and reproducible coverage profile of
the reference genome. The saturation correlations of 5 ng cfDNA input are consistent with the 10
ng genomic DNA (gDNA) input (Figure 9e-f). Additionally, the results showed robust genomewide inter-replicate Pearson correlation (Figure 10a). Together, these results suggest that cfMBDseq can generate a high quality methylome that is equivalent to standard MBD-seq while allowing
ultra-low DNA input.
As the 1000 ng input has the highest genome-wide inter-replicate correlation, we further
investigated if an increased amount of filler DNA can enhance the performance of the reaction.
We thus increased the DNA input by adding more filler DNA, with the quantity of cfDNA
unchanged (in total 100, 500, 1000 ng). However, we didn’t observe an improved methylation
enrichment even when the amounts of MethylCap protein and beads were adjusted accordingly. In
fact, the higher amount of filler DNA reduced the performance of CpG-islands-centered
methylation enrichment (Figure 10b-c) and increased background noise (Figure 10d). These
results can be explained by the increased amount of methylated filler DNA overshadowed the trace
amount of methylated cfDNA. Thus, we decided 100 ng as an optimal DNA input, due to the
robust recovery of CpG-islands-centered regions with low noise.
2.3.6 Additional wash and elution did not improve enrichment
Given the confirmed MethylCap protein to DNA ratio and amount of methylated filler DNA, we
evaluated other experimental conditions to see if the methylation enrichment performance can be
further improved. First, we examined the effect of a more stringent wash condition on non-specific
binding. However, double wash did not significantly increase the percentage of CpG island reads
when compared to the standard wash. The additional wash also did not decrease the percentage of
sequence reads on the open sea regions, where non-specific bindings are most likely to occur
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(Figure 11a). Likewise, there was no significant difference on the peak and noise between the
standard wash and double wash (Figure 11b). Since the additional wash can take much more time,
we will not consider it as an optimization.
Second, we examined the effect of the elution buffer salt concentration on methylation enrichment.
We performed single fraction elution using the three different elution buffers (High, Medium, Low)
provided in the MethylCap kit. Theoretically, an increased salt concentration may preferentially
enrich regions with higher CpG density [219]. However, we did not observe a notable shift on the
coverage by density plot, nor sequence reads percentage difference on each CpG annotations
(Figure 12a-c). For example, the signals at the CpG island MGAT3 showed no difference among
the three elution buffers (Figure 12d). The finding that MethylCap protein (MeCP2) is not
sensitive to the salt concentration of elution buffer has been reported previously [220,221]. We also
investigated multiple fractions elution, that is, sequential elution with low, medium, and high salt
elution buffer from one capture reaction. The coverage by density plot illustrated robust
methylation enrichment in both the first fraction (low salt elution buffer) and the pool of three
fractions (Figure 12e). But the second fraction (medium salt), the third fraction (high salt), and
the pool of the second and third fractions had very low coverage (Figure 12e). These results
demonstrated the importance of the first fraction of elution, no matter the salt concentration of
elution buffer, due to the intrinsic limitation of ultra-low DNA input. In summary, our results
suggest an optimal condition for low input methylation enrichment includes 0.2 μg MethylCap
protein and 3 μl beads for 100 ng DNA mixture (cfDNA + methylated filler DNA), standard wash,
and single fraction elution.
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2.3.7 Comparison of cfMBD-seq with other technologies
To evaluate the methylation capture accuracy of cfMBD-seq, we calculated its sensitivity
(proportion of methylated CpG islands detected) and specificity (1 - proportion of non-methylated
CpG islands detected). We used Infinium HM450K data (Gene Expression Omnibus (GEO):
GSE55491, peripheral blood mononuclear cell (PBMC) from N=5 healthy controls) as a standard
to determine whether a CpG island was methylated or non-methylated. It is known that the
methylation level between neighboring CpG sites is positively correlated. Therefore, to obtain a
comparable measurement between cfMBD-seq and methylation array, we averaged the beta-values
of adjacent CpG sites within each CpG island and defined the methylation status of that CpG island.
We then built a logistic regression model for all CpG islands on the microarray using normalized
read counts from cfMBD-seq and methylation status from microarray (AUC=0.995, Figure 13a).
At the cutoff of 13.25, derived from the intersection of the specificity and sensitivity curves
translated to normalized read counts, the sensitivity of cfMBD-seq is 0.94 and the specificity is
0.98. Namely, at this threshold, cfMBD-seq detected 94% of the methylated CpG islands that were
reliably detected by Infinium methylation array, while correctly classifying 98% of nonmethylated sites.
To determine the performance of cfMBD-seq over existing methylation enrichment assays, we
compared cfMBD-seq with a previously published low input MBD-seq protocol (N=4 from GEO:
GSM2593327-GSM2593330) that did not use filler DNA [141]. Different from cfMBD-seq, this
low input MBD-seq protocol has a very low recovery rate of the CpG island regions (median 19.95%
[(Q1) 19.25%-(Q3) 20.11%]) and a relatively high recovery rate of the open sea regions (14.30%
[14.24%-14.49%]) (Figure 13b-c). Worst of all, the overall coverage is low, which makes it
difficult to discriminate methylated fragments from non-specific fragments (Figure 13d). We next
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compared cfMBD-seq with cfMeDIP-seq (N=24 cancer-free individuals from published dataset)
which showed adequate performance on capturing tumor-specific methylation in cfDNA [133-135].
According to the summary QC from the RaMWAS package, we observed a higher percentage of
reads that passed the filter in cfMBD-seq (83.15% [82.93%-83.68%]) than in cfMeDIP-seq (74.90%
[74.53%-75.45%]) and a lower duplicate rate (3.45% [3.40%-3.90%] vs. 12.00% [9.00%19.23%]). Taken together, cfMBD-seq generated higher quality and more informative sequencing
data than cfMeDIP-seq (79.60% [79.15%-80.43%] vs. 62.65% [55.60%-66.65%]) (Table 1). For
the CpG annotation-based results, cfMBD-seq showed a significantly higher recovery rate at CpG
islands (60.13% [58.78%-60.81%] vs. 38.16% [37.21%-41.28%], Figure 13b) and a slightly
higher recovery rate at combined CpG islands/shores/shelves (94.81% [94.61%-94.98%] vs. 90.90%
[90.91%-91.55%], Figure 13c), suggesting that cfMBD-seq preferentially enriches CpG islands,
while cfMeDIP-seq has more signal on CpG shores and CpG shelfs. This finding is consistent with
the coverage by CpG density plot, where cfMBD-seq peaks at higher CpG density than cfMeDIPseq (29.98 [29.54-30.33] vs. 22.88 [22.37-23.50], Figure 13d). The comparison between cfMBDseq, low input MBD-seq, and cfMeDIP-seq was summarized in Table 1. To better demonstrate
the reproducibility of cfMBD-seq, we showed a snapshot of a genomic region with consecutive
CpG islands (chr8:86,703,816-86,880,439). We observed peaks with high similarity among
cfMBD-seq (1 to 100 ng input DNA), standard MBD-seq (1000 ng), cfMeDIP-seq (1 to 10 ng),
and standard MeDIP-seq (100 ng) (Figure 14). We then compared the signal peaks among
different methylation profiling technologies. We showed that cfMBD-seq also recapitulated
methylation profiles from RRBS (1000 ng) and WGBS (2000 ng) (Figure 15). All these findings
suggest that cfMBD-seq, allowing ultra-low DNA input as starting material, can reliably detect
genome-wide DNA methylation signal with high accuracy. These features demonstrate that
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cfMBD-seq is a promising tool in the discovery of novel biomarkers for cancer detection and
management.
2.4 Discussion
In this study, we further optimized the MBD-seq protocol to enable methylation enrichment from
ultra-low DNA input. The most critical modification for this purpose is to decrease the amount of
MethylCap protein proportionally according to the MethylCap protein/DNA ratio recommended
by the manufacturer’s protocol. The 2:1 MethylCap protein/DNA ratio ensures a high specificity
of methylation capture (Figure 6). Unlike MethylCap protein, the amounts of magnetic beads had
less impact on the methylation enrichment. By comparing across different methylation status of
filler DNA, we showed that methylated filler DNA is also indispensable to ensure the specificity
of methylation capture (Figure 7). Using as little as 1 ng DNA input, cfMBD-seq is able to
generate a saturated and reproducible coverage profile of the reference genome (Figure 9). Also,
the methylome from 1 ng DNA generated by cfMBD-seq is highly correlated to the methylome
from 1000 ng DNA generated by standard MBD-seq (Figure 10). However, other attempts such
as using more filler DNA, applying double wash, or using elution buffer with different salt
concentration cannot improve the performance of methylation enrichment (Figure 11,12). To
evaluate if the methylation signals captured by cfMBD-seq are real, we compare our sequencing
data with the most commonly used HM450K assay by a logistic regression model. The results
showed that cfMBD-seq detected 94% of the methylated CpG islands detected by HM450K, while
correctly classifying 98% of non-methylated sites (AUC=0.995) (Figure 13a). cfMBD-seq also
performs better than a previously published low input MBD-seq protocol in the methylation
enrichment of CpG islands-centered regions [141]. Most importantly, cfMBD-seq outperforms
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cfMeDIP-seq in the enrichment of fragments with higher CpG density such as CpG islands (Figure
13b-d).
The differences between standard MBD-seq and standard MeDIP-seq have been described in a
previous study: MeDIP commonly enriches methylated regions with a low CpG density, while
MBD captures a broad range of CpG densities and identifies the greatest proportion of CpG islands
[140]. It is known that CpG-rich fragments do not undergo complete denaturation into single

stranded DNA which is required for an efficient MeDIP capture and may explain why MeDIP-seq
is less sensitive toward fragments with high CpG density. In contrast, MBD capture does not
require DNA denaturation because the MethylCap protein is sensitive toward double stranded
DNA. Therefore, temperature control of DNA-protein mixture during MBD capture is less strict
than MeDIP capture. In addition, MBD enrichment in cfMBD-seq can be finished within 5 hours
(including 3 hours of incubation), while cfMeDIP enrichment needs overnight incubation. Thus,
the reaction of MBD enrichment is less time-consuming. Overall, both cfMBD-seq and cfMeDIPseq are reliable ultra-low input methylation profiling assays. cfMBD-seq is a method of choice for
interrogating regulation of gene expression (methylation changes in CpG islands), while cfMeDIPseq would be preferable in investigating transcriptional regulation of non-coding RNAs
(methylation changes in gene bodies and CpG shores).
There are a few caveats to ensure successful cfMBD-seq. First, the quality of the MethylCap
protein is very important. We notice that the use of MethylCap protein that has experienced
multiple freeze–thaw cycles can negatively impact the data quality. Because the MethylCap
protein is used with 10-fold dilution before adding to the reaction, it can be used for much more
reactions than the standard MBD capture. Therefore, we recommend splitting the MethylCap
protein into multiple aliquots to minimize the freeze-thaw cycles and using fresh diluted protein
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for each batch. Second, the success of the methylation enrichment reaction must be validated by
qPCR to detect recovery of spiked-in control. The specificity of the reaction should be ≥99%
before proceeding to the next step. Third, accurate library quantification is critical. As methylated
filler DNA is used in the methylation enrichment, fluorometer-based library quantification
methods may inevitably count filler DNA. Therefore, qPCR-based library quantification is
recommended because it will only quantify the amounts of amplifiable DNA (adapter ligated
cfDNA). Lastly, adequate sequencing depth is crucial for high quality data. Based on the saturation
analysis, at least 30 million mapped reads are required to generate a saturated and reproducible
coverage profile. The cost of the entire cfMBD-seq workflow, starting from cfDNA extraction
through the generation of sequencing data (single-end and pooling 12-15 indexed libraries using
the Illumina NextSeq 550 platform), is less than $300 per sample. This cost-effective feature
allows large-scale methylome-wide association analysis that is crucial for the establishment of a
prediction model with high accuracy.
It is worth mentioning that the current study also has some limitations. First, it is well known that
the methylation status is different between individuals. The differences observed among cfMBDseq, low-input MBD-seq, and cfMeDIP-seq could be partly attributed to the difference in different
plasma samples that were used. Thus, further validation is required. Second, the main application
of cfMBD-seq is to identify cancer biomarkers in cfDNA. However, current study was limited to
technology development and optimization. Further study in patient’s plasma samples is needed to
test the feasibility of cfMBD-seq in clinical settings, in particular to elaborate how well this
technology can differentiate the tumor-derived cfDNA methylation signals from the high
background cfDNA from normal blood cells.
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Overall, our study demonstrates the potential benefits of using cfMBD-seq to profile the
methylome of cfDNA with ultra-low DNA input. Current results provide justification for further
validation using case and control plasma samples from different malignancies to perform
differential methylation analyses. Since enrichment-based methods are analyzed by comparing the
relative abundance of sequenced fragments, cfMBD-seq shares similar data analysis workflows
with cfMeDIP-seq for the identification of DMRs and other downstream machine learning
analyses. Another potential for cfMBD-seq is the use in other methylome-wide investigations that
are limited by DNA yield. We confidently believe that cfMBD-seq, being non-invasive and costeffective, has a great potential in identifying biomarkers for cancer detection and management.
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Figure 5. Schematic diagram of cfMBD–seq and CpG annotations
a) Schematic workflow of cfMBD–seq protocol. From cfDNA extraction to generation of
methylation profile. b) Schematic diagram of CpG annotations. Numbers on the left (in brackets)
represent the percentage of the CpG features in the human genome. For example, CpG islands
account for only 0.7% of the human genome. Numbers on the right represent total number of
features. For example, there are 28,691 CpG islands in the hg19 reference genome.
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Figure 6. Reduced MethyCap protein improves low-input methylation enrichment
a) & b) Percentage of sequence reads mapped on CpG islands and CpG islands/shores/shelves
across different amount of MethyCap protein and magnetic beads. (N=4 for the first condition,
N=3 for other conditions. Mean with the standard error of the mean (SEM).) c) Coverage by CpG
density plot across different amount of MethyCap protein and magnetic beads. Coverage is defined
as average number of fragments covering CpGs. CpG density is number of CpGs per fragment. d)
CpG density at peak and noise under different MethyCap protein and magnetic beads. CpG density
at peak is CpG density at the point of highest coverage on the ‘coverage by CpG density plot’ (left
y-axis). Noise is the ratio of average non-CpG coverage to average CpG coverage (right y-axis).
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Figure 7. Methylated filler DNA is needed for low input methylation enrichment
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Figure 8. Important pre-sequencing quality controls
a) & b) Library concentration (ng/μl) measured by Qubit assay across different conditions. c) & d)
Specificity of methylation enrichment measured by qPCR, using methylated and unmethylated
spiked-in A. thaliana DNA control.
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Figure 9. Saturation analysis across different DNA input
Saturation analysis from the MEDIPS R package for the sequencing result of cfMBD-seq using
different HCT116 DNA input (1, 10, 100, and 1000 ng) (a-d) and 3 ng cfDNA input (e-f). The
saturation analysis determines if the given set of mapped reads is sufficient to generate a saturated
and reproducible coverage profile of the reference genome.
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Figure 10. Different amount of input DNA in cfMBD-seq
a) Genome-wide Pearson correlations of normalized read counts between cfMBD-seq signal for
1-1000 ng of input HCT116 DNA (2 technical replicates per concentration). The input control is
from an input library of a ChIP-seq study (ENCODE: ENCFF280GWX). Log transformed counts
were used in the scatter plots. b) & c) Percentage of sequence reads mapped on CpG islands and
CpG islands/shores/shelves across different mixture of cfDNA and filler DNA. (N=4 for the first
condition, N=2 for other conditions. Mean with SEM.) d) CpG density at peak (left y-axis) and
noise (right y-axis) of different mixture of cfDNA and filler DNA.

54

a

b

CpG annotations coverage

CpG density at peak

Single wash
Double wash

60

Peak and Noise

40
20

0.4

30

0.3

20

0.2

10

0.1

0

0.0

CpG density at peak
Noise

h
as

as

W
bl
e
D
ou

O

pe

St
an
da
rd

n

W

se

a

s
sh
el
ve
C
pG

re
s
sh
o
C
pG

C
pG

is
la
nd

s

h

0

40

Noise

Mapped reads (%)

80

Figure 11. Additional wash does not improve methylation enrichment
a) Percentage of sequence reads mapped on different CpG annotations across different wash
conditions. (N=4 for each condition. Mean with SEM.) b) CpG density at peak (left y-axis) and
noise (right y-axis) of different wash conditions.
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Figure 12. Effect of elution buffer in cfMBD capture
a) Coverage by CpG density plot across elution buffers with different salt concentration. b) CpG
density at peak (left y-axis) and noise (right y-axis) of different elution buffers. c) Percentage of
sequence reads mapped on different CpG annotations across different wash conditions. (Mean with
SEM.) d) Genome Browser snapshot of cfMBD-seq signal at the CpG island of MGAT3, which is
used as an example in the manual of MethylCap kit. Data were processed by MEDIPS package for
RPKMs normalization and were exported as wiggle files for visualization. e) Coverage by CpG
density plot across multiple fractions of elution conditions.
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Figure 13. Comparison of cfMBD-seq with low input MBD-seq and cfMeDIP-seq
a) Receiver operating characteristic curve and corresponding area under the ROC curve for
methylation status of CpG islands from Infinium HM450K data predicted by cfMBD-seq
normalized read counts. b) & c) Percentage of sequence reads mapped on different CpG
annotations (b) and CpG islands/shores/shelves (c) of cfMBD-seq (N=8), cfMeDIP-seq (N=24),
and low input MBD-seq (N=4). (Mean with SEM.) d) Coverage by CpG density plot of cfMBDseq, cfMeDIP-seq, and low input MBD-seq.
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Figure 14. cfMBD-seq shares similar methylation profile with cfMeDIP-seq
Genome Browser snapshot of different input of HCT116 DNA signal by cfMBD-seq and cfMeDIP-seq across a region with consecutive
CpG islands (chr8:86,703,816-86,880,439). Data were processed by MEDIPS package for RPKMs normalization and were exported as
wiggle files for visualization.
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Figure 15. cfMBD-seq recapitulates methylation profiles from other technologies
Genome Browser snapshot of HCT116 cfMBD-seq signal across chr8:145,095,942-145,116,942, at different starting DNA input (1 to
100 ng), compared with cfMeDIP-seq (Gene Expression Omnibus (GEO): GSE79838), RRBS (ENCODE: ENCSR000DFS), and
WGBS (GEO: GSM1465024) data. For cfMBD-seq and cfMeDIP-seq, the y axis indicates RPKMs normalized reads; for RRBS, red
and green blocks represent hypermethylated and hypomethylated CpGs, respectively. For WGBS track, peak heights indicate
methylation level.
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Table 2. Comparison among cfMBD-seq, Low input MBD-seq, and cfMeDIP-seq
cfMBD-seq (N=8)

Low input MBDseq (N=4)
Experiment

cfMeDIP-seq (N=24)

Filler DNA

Methylated DNA only

No filler

Mixture of methylated
and unmethylated DNA

DNA Denaturation

Not required

Not required

Required

Capture protein

MeCP2

MBD2

Anti-5mc

Capture time

5 hours (including 3
hours incubation)

5 hours (including
3 hours
incubation)

23 hours (including 17
hours overnight
incubation)

Quality Control
Reads passed filter
Duplicate rate
Used reads
Reads on CpG
islands
Reads on CpG
islands/shores/shelves

83.15%
85.40%
[82.93%-83.68%]
[85.03%-85.70%]
3.45%
2.65%
[3.40%-3.90%]
[2.60%-2.78%]
79.60%
82.75%
[79.15%-80.43%]
[82.25%-83.10%]
Methylation Enrichment
60.13%
19.95%
[58.78%-60.81%]
[19.25%-20.11%]
94.81%
85.70%
[94.61%-94.98%]
[85.51%-85.76%]

29.98
[29.54-30.33]
Median along with [first quartile (Q1) - third quartile (Q3)] are shown.
CpG density at peak
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15.76
[15.41-15.88]

74.90%
[74.53%-75.45%]
12.00%
[9.00%-19.23%]
62.65%
[55.60%-66.65%]
38.16%
[37.21%-41.28%]
90.90%
[90.91%-91.55%]
22.88
[22.37-23.50]

Chapter 3: Cancer detection and classification by hypermethylated CpG islands
This section was previously published by Cancers, a peer-reviewed, open access journal of
oncology, published semimonthly online by MDPI.
[222] Huang, J.; Soupir, A.C.; Schlick, B.D.; Teng, M.; Sahin, I.H.; Permuth, J.B.; Siegel, E.M.;

Manley, B.J.; Pellini, B.; Wang, L. Cancer Detection and Classification by CpG Island
Hypermethylation Signatures in Plasma Cell-Free DNA. Cancers (Basel) 2021, 13,
doi:10.3390/cancers13225611.
3.1 Introduction
Lung and colorectal cancer are among the most common causes of cancer-related deaths in the US,
while pancreatic cancer is the deadliest form of solid malignancy with an alarming 10% five-year
survival rate [223]. Detection of cancer at an early stage before metastasis can significantly reduce
the mortality of these malignances. Methylation in cfDNA is a promising biomarker for the early
detection of cancer. CpG islands-specific hypermethylation is a key characteristic of the cancer
methylome [45]. Hypermethylation of CpG island can affect the cell cycle, DNA repair,
metabolism, cell-to-cell interaction, apoptosis, and angiogenesis, all of which are involved in
tumorigenesis and cancer progression [224]. CpG island hypermethylation has been described in
almost every tumor type [45]. One of the most well-studied DNA methylation signatures is the
methylation of SEPT9 promoter, which is an FDA-approved biomarker for colorectal cancer
detection [225]. A blood-based test for methylated SEPT9 (Epi proColon) has been applied to
plasma cfDNA in patients undergoing colorectal cancer screening, however this test has a
relatively low sensitivity for the detection of early-stage colorectal cancer [226]. Additionally, Epi
proLung is another plasma-based DNA methylation test that detects methylated PTGER4 and
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SHOX2 promoters for the detection of lung cancer. Most recently, GRAIL lunched a methylationbased blood test called Galleri that could detect a range of cancers. The trail results from in a small
number of studies showed that Galleri was able to detect over 50 types of cancer even at an early
stage. Galleri has so far been promising, but it needs to be tested further in larger trials. Overall,
CpG island hypermethylation has demonstrated its great versatility and potential for the detection
and management of cancer [227].
Enrichment-based methylation profiling methods such as methyl-CpG-binding domain sequencing
(MBD-seq) and methylated DNA immunoprecipitation sequencing (MeDIP-seq) have shown
similar sensitivity and specificity for the detection of differentially methylated regions (DMRs)
when compared to bisulfite conversion-based methods [131]. Nonetheless, such technologies are
restricted to tumor tissue application due to the need of high amounts of DNA input. To address
this issue, Shen et al. optimized the MeDIP-seq protocol to allow methylome analysis of small
quantities of cfDNA, termed cfMeDIP-seq [134,135]. cfMeDIP-seq has shown high accuracy in the
classification of a wide variety of cancer types [134] and characterization of renal cell carcinoma
patients across all stages [136,137]. To expand the use of enrichment-based methods in cfDNA, we
optimized the MBD-seq protocol for low input cfDNA methylation profiling, termed cfMBD-seq
[101]. We previously showed that cfMBD-seq provides higher sequencing data quality with more

sequenced reads passing filter and a lower duplicate rate than cfMeDIP-seq. cfMBD-seq also
outperforms cfMeDIP-seq in the enrichment of high CpG density regions (i.e., CpG islands) [101].
However, the clinical feasibility of cfMBD-seq is unknown. Based on our previous findings, we
hypothesized that cfMBD-seq can identify hypermethylated CpG islands as biomarkers for cancer
detection and classification. In this study, we applied cfMBD-seq to the plasma samples of patients
with advanced lung, colorectal, and pancreatic cancer and cancer-free individuals to determine
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whether cfMBD-seq can reliably identify differentially methylated regions (DMRs) between cases
and controls. We also investigated whether these DMRs enable accurate discrimination between
different cancer types (Figure 16).
3.2 Material and methods
3.2.1 Sample acquisition and clinical cohort
The study subjects were recruited at Moffitt Cancer Center following Total Cancer Care protocol
(https://moffitt.org/research-science/total-cancer-care/). A total of 53 subjects including colorectal
(N=13), lung (N=12), pancreatic (N=12) cancer patients, and non-cancer controls (N=16) were
used in this study (Clinical demographic characteristics in Table 3). All cancer patients had
metastatic disease at the time of sample collection. Most cancer patients had adenocarcinoma
histology: 11 of 13 were colorectal adenocarcinoma; 9 of 12 were lung adenocarcinoma; and 10
of 12 were pancreatic adenocarcinoma. Subjects in the non-cancer cohort were specifically
negative for any form of cancer. Samples were randomized and blinded during cfDNA extraction,
library preparation, and sequencing. Samples were unblinded during data analysis. All patients
provided written informed consent. The study was approved by Institutional Review Boards (IRB#
00000971) of H. Lee Moffitt Cancer Center & Research Institute (MCC 20563).
3.2.2 Plasma sample collection
Moffitt Cancer Center Total Cancer Care followed standard operating procedure for blood
sampling: Whole blood specimens were obtained by routine venous phlebotomy and collected in
Purple top EDTA blood tubes. Plasma was isolated from whole blood at the time of subject
enrollment. Centrifugation of whole blood was performed at 1300 x g for 10min at room
temperature. Plasma layer was transferred into 1.5 ml cryovials and stored as three 1mL aliquots.
Plasma samples were frozen immediately at -80 ℃ after isolation.
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3.2.3 cfDNA extraction
Plasma samples were thawed and centrifuged at 3,000g for 15 mins to ensure complete depletion
of cell debris. cfDNA was extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen;
Hilden, Germany) following the manufacturer’s protocol, except for the addition of carrier RNA
in Buffer AVE. All cfDNA eluates were quantified by a Qubit Fluorometer using the iQuant™
NGS-HS dsDNA Assay Kit (Genecopoeia; Rockville, MD, USA) and then submitted to Moffitt
Cancer Center Molecular Genomics Core for D1000 ScreenTape Assay (Agilent; Santa Clara, CA,
USA) to ensure the absence of high molecular weight DNA contamination from white blood cell
lysis.
3.2.4 Filler DNA generation
To generate filler DNA, Enterobacteria phage λ DNA was polymerase chain reaction (PCR)
amplified with the GoTaq Master Mix (Promega; Madison, WI, USA). Primers sequences are as
follows: Forward primer 5’- CGATGGGTTAATTCGCTCGTTGTGG-3’, reverse primer 5’GCACAACGGAAAGAGCACTG-3’. The 274 bp amplicons were treated with CpG
methyltransferase (M.SssI; Thermo Fisher Scientific) to methylate amplicons. Methylated
amplicons were purified by the DNA Clean & Concentrator-5 Kit (ZYMO Research; Irvine, CA,
USA) and quantified by Qubit Fluorometer. CpG methylation-sensitive restriction enzyme
HpyCH4IV (New England BioLabs; Ipswitch, MA, USA) digestion followed by agarose gel
electrophoresis was performed to ensure complete methylation of filler DNA.
3.2.5 Library preparation
cfDNA was subjected to end repair/A-tailing and adapter ligation using the KAPA Hyper Prep Kit
(Kapa Biosystems; Wilmington, MA, USA) with the sequencing adapter from NEBNext Multiplex
Oligos for Illumina (New England BioLabs). The amount of adapter was adjusted to an adapter:

64

insert molar ratio of 200:1. Adapter-ligated DNA were purified with 0.8 x SPRI Beads (Beckman
Coulter; Pasadena, CA, USA) and digested with USER enzyme (New England BioLabs) followed
by purification with the DNA Clean & Concentrator-5 Kit. Adapter ligated DNA was first
combined with methylated filler DNA to ensure that the total amount of input for methylation
enrichment was 100 ng, which was further mixed with 0.2 ng of methylated and 0.2 ng of
unmethylated spike-in A. thaliana DNA from the DNA Methylation control package (Diagenode,
Seraing, Belgium).
3.2.6 cfMBD methylation capture
The DNA mixture was subjected to methylation enrichment using the MethylCap Kit (Diagenode)
following the manufacture’s protocol with some modifications. Total volume brought up by Buffer
B was reduced from 141.8 μl to 136 μl to minimize DNA waste. The amount of MethylCap protein
and magnetic beads were decreased proportionally according to the recommended input DNA to
protein and beads ratio (0.2 μg protein and 3 μl beads per 100 ng DNA input). MethylCap protein
was 10-fold diluted to 0.2 μg/μl using Buffer B. Single fraction elution with High Elution Buffer
was applied. The eluted fraction was purified by DNA Clean & Concentrator-5 Kit. The purified
DNA was divided into two parts, one for qPCR (PowerUp™ SYBR™ Green Master Mix, Thermo
Fisher) amplification of spiked-in DNA for methylation enrichment quality control, another for
library amplification. Recovery of the spiked-in methylated and unmethylated controls can be
calculated based on cycle threshold (Ct) value of the enriched and unenriched samples. Specificity
of the capture reaction can be calculated by (1 - [recovery of unmethylated control DNA over
recovery of methylated control DNA]) × 100). The specificity of the reaction should be ≥99%
before proceeding to the next step.
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3.2.7 DNA sequencing and alignment
Methylation-enriched DNA libraries were amplified as follows: 95 °C for 3 min, followed by 12
cycles of 98 °C for 20 s, 65 °C for 15 s and 72 °C for 30 s and a final extension of 72 °C for 1 min.
During the amplification, unique indexes from primer (NEBNext Multiplex Oligos for Illumina)
were added to the sequencing adapter of each sample. The amplified libraries were purified using
1 x SPRI Beads followed by a dual size selection (0.6 x followed by 1.2 x) to remove any adapter
dimers. All final libraries were first quantified with the Qubit assay and qPCR-based assay using
the NEBNext® Library Quant Kit for Illumina® (New England BioLabs) and then submitted to
Moffitt Cancer Center Molecular Genomics Core for D1000 ScreenTape Assay for the
measurement of fragment size. Libraries were sequenced on the NextSeq 550 platform (Illumina;
San Diego, CA, USA), high-output 75 bp single-end read, multiplexed as 12 samples per run. After
sequencing, quality control for raw sequence reads was performed using fastp (Version 0.20.1)
[155] with the default settings. The sequence reads were then aligned to the human genome (hg19)

using Bowtie-2 (Version 2.4.2) [166] with default settings. After the alignment, the generated sam
files were converted to bam files, followed by sorting, indexing, removal of duplicate reads, and
extraction of read count on chr1 - chr22 using SAMtools (Version 1.11) [216] ‘view’, ‘sort’, ‘index’,
and ‘markdup’ command lines.
3.2.8 Quality control of methylation enrichment
R (Version 4.0.3 or greater) package RaMWAS (Version 1.12.0) [175] with default parameters was
used for quality control of overall mapping quality and calculation of non-CpG reads percentage,
non-CpG/CpG coverage (noise), and CpG density at peak. CpG annotation reference was obtained
from R package annotatr (Version 1.16.0): annots='hg19_cpgs'. BEDtools (Version 2.28.0) [217]
‘coverage’ command line was used to call the number of sequenced reads on each CpG feature.
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Read counts of each CpG feature and each sample was combined as a count matrix. Transcripts
per kilobase million (TPM) normalization was performed before comparing the percentage of CpG
feature read counts between different groups.
3.2.9 Differential methylation analysis of cfMBD-seq data
Rows with inter CpG regions and zero read count among all samples were filtered out from CpG
feature raw count matrix. Filtered matrix were further subset for single cancer type and non-cancer
control and fit a negative binomial model to call DMRs at Benjamini-Hochberg false discovery
rate (BH-FDR) <0.1 (Wald test) using R package DESeq2 (Version 1.32.0) [191]. R package
EnhancedVolcano (Version 1.10.0) [228] was used for visualization of fold change and BH-FDR
(q value) for all CpG islands and extended CpG islands. Unsupervised hierarchical clustering was
performed on Partek genomics suite (Version 7.0) for visualization of DMCGIs, using log
transformed DESeq2 normalized values, z scores, Euclidean distance, and Ward Clustering. R
package pcaExplorer (Version 2.18.0) [229] was used for principal component analysis of DESeq2
normalized values of top 1,000 differentially hypermethylated CpG islands (DMCGIs) selected by
highest row variance. The 95% confidence ellipses for the case and control were displayed. Plasma
derived DMCGIs with fold change >2 were used for intersection with tissue derived DMCGIs.
3.2.10 Methylation analyses for tumor tissue specific DMCGIs
HM450K data of primary tumors and adjacent normal tissues from patients with colon
adenocarcinoma (COAD) (35 pairs), lung adenocarcinoma (LUAD) (21 pairs), and pancreatic
adenocarcinoma (PAAD) (10 pairs) were acquired from TCGA. HM450K data of non-cancer
individuals’ PBMCs (N=61) from GEO (non-smoker controls in GSE53045) were also used to
deconvolute clonal hematopoiesis effect. R package minfi (Version 1.36.0) [181] was used to call
DMCs (Mean of delta beta value >0.2 and BH-FDR <0.1) between primary tumor and normal
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tissue / non-cancer PBMCs. R package EnhancedVolcano was used for visualization of delta beta
value and q value (FDR) for all HM450K CpG sites. To make tissue derived DMCs comparable
with plasma derived DMRs, all DMCs were annotated to a hg19 HM450K annotation file and their
corresponding CpG islands were identified for intersection. Tissue-derived DMCGIs were
identified by intersecting DMCGIs from plasma cases vs controls, primary tumors vs. normal
tissues, and primary tumors vs. PBMCs. Tissue-specific DMCGIs were identified by intersecting
colorectal, lung, and pancreas-derived DMCGIs. Venn diagrams were used for visualization of the
intersection.
3.2.11 Machine learning analyses
Two independent cohorts were used for machine learning analyses: cfMeDIP-seq cohort and
HM450K cohort. cfMeDIP-seq data of lung cancer patients (N=80) and non-cancer individuals
(N=86) were used for evaluation of early cancer detection in plasma cfDNA. An independent
HM450K cohort including primary tumors from TCGA (N=210 for COAD, N=385 for LUAD,
and N=162 for PAAD) was used for evaluation of cancer classification performance. HM450K
data were converted to a CpG islands beta value matrix by calculating the mean beta values of
CpG sites annotated to the same CpG island. R package Caret (Version 6.0-88) [230] was used to
partition the discovery cohort data into 100 class-balanced independent training and testing sets in
an 80–20% manner. Top overlapping DMCGIs between cfMBD-seq and HM450K datasets were
selected for predictive modeling analyses. R package glmnet (Version 4.1-2) [231] was used to
preform regularized logistic regression model on the training sets. LASSO regularization method
(alpha=1) with 10-fold cross validation was applied to determine minimum lambda penalty value.
The entire process was repeated 100 times to prevent training-set biases. DMCGIs with non-zero
coefficient across all repeats were determined as cancer classifiers. Performance of the predictive
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models was evaluated on the held-out testing set using ROC statistics. R package Rtsne (Version
0.15) [232] was used for generation of t-sne plot to visualize cancer classification in cfMBD-seq,
cfMeDIP-seq, and HM450K data sets.
3.2.12. Data availability statement
R scripts and git bash used to generate the results in this study are available on GitHub
(https://github.com/LiangWangLab/cfMBD-seq-clinical).

The

cfMBD-seq

next-generation

sequencing data of patient plasma samples are available upon request from the author to comply
with institutional ethics regulations. Deidentified cfMBD-seq raw read count matrices for all CpG
islands are available in https://www.mdpi.com/article/10.3390/cancers13225611/s1. The
cfMeDIP-seq sequencing data are available upon request from the Shen et al. group [134]. The
HM450K dataset is publicly available in The Cancer Genome Atlas and Gene Expression Omnibus.
Primary tumor and adjacent normal tissue data can be acquired using the manifest in
https://www.mdpi.com/article/10.3390/cancers13225611/s1. Peripheral blood mononuclear cell
data can be found in GSE53045 (non-smoker controls).
3.3 Results
3.3.1 Significant enrichment of methylated CpG islands in cfDNA
To study the clinical feasibility of cfMBD-seq, we retrospectively profiled cfDNA methylome of
53 blood samples from patients with metastatic carcinoma of the colon/rectum (N=13), lung
(N=12), and pancreas (N=12), and from cancer-free individuals (N=16). We quantified cfDNA
concentration from plasma samples and showed that cancer patients had higher cfDNA yield than
non-cancer controls (Figure 17a). To investigate methylation capture efficiency of cfMBD-seq,
we compared spiked-in controls between methylated and unmethylated A. thaliana DNA in the
capture reaction and observed a median specificity at 99.3% [99.16% (Q1) - 99.43% (Q3)] across

69

all samples (Figure 17b). From sequencing data, we filtered out duplicate reads and reads with
low alignment scores from total sequence reads (41.62 [38.75 - 44.43] million) and obtained 35.33
[32.77 - 37.37] million high-quality reads (Figure 17c). We then investigated genome-wide
methylation enrichment and found that the number of captured fragments without any CpG tandem
accounted for only 1.47% [1.33% - 1.59%] of high-quality reads (Figure 17d). The coverage ratio
of fragments without any CpG tandem to fragments with at least one CpG, known as noise, was
0.15 [0.13 - 0.17] (Figure 17e). The median CpG density of fragments with the highest read
coverage was 25.2 [24.2 - 25.7] (Figure 17f), corresponding to high-CpG density regions - CpG
islands. Intrigued by the high sequencing coverage on CpG islands, we further studied the
distribution of sequence reads by calculating the percentage of normalized reads on different CpG
annotation features (i.e., CpG islands, CpG shores, CpG shelves, and inter CpG regions). We found
a median of 42.16% [39.47 - 45.15] of reads mapped to CpG islands, when CpG islands only
account for 0.7% of the hg19 reference genome (Figure 18a&d). Since methylation alterations
may occur at a short distance away from the CpG islands [218], we also calculated the sum of reads
mapped to extended CpG islands (i.e., CpG islands, CpG shores, and CpG shelves). A median of
91.46% [90.89% - 92.13%] of reads were mapped to the extended CpG islands, which accounts
for only 6.72% of the reference genome (Figure 18b-d). These results demonstrate that most of
the sequence reads captured by cfMBD-seq were significantly enriched on CpG island-centered
regions, illustrating successful cfMBD-seq methylation enrichment and library construction across
all samples.
3.3.2 Differential methylation analyses between cases and controls
To identify differences in methylation patterns between cases and controls, we generated a read
count matrix for each cancer type versus non-cancer control. In this matrix, each row represents a
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different CpG feature, and each column represents a unique individual sample. We then removed
rows annotated as inter CpG and rows with 0 read count across all samples and obtained 115459
genomic regions. Next, we performed differential methylation analysis based on a negative
binomial model of feature counts at a significance level of 0.1 using Benjamini-Hochberg false
discovery rate (BH-FDR) and identified 2722, 3033, and 2831 DMRs for colorectal, lung, and
pancreatic cancer, respectively (Figure 19a-c). We further filtered these DMRs using a more
stringent criteria: absolute fold change >2, which resulted in 2009 DMRs (2007 hypermethylated
and 2 hypomethylated) in colorectal cancer, 1818 DMRs (1814 hypermethylated and 4
hypomethylated) in lung cancer, and 1488 DMRs (1482 hypermethylated and 6 hypomethylated)
in pancreatic cancer. As the majority of the remaining DMRs were hypermethylated, and most of
them were CpG islands (97%, 85%, and 93% in colorectal, lung and pancreatic cancer patients,
respectively), to enhance computational efficiency, we reduced our dataset to 26441 CpG islands
and applied the same criteria for differential methylation analysis (BH-FDR<0.1 and fold
change >2). This optimized analysis identified 1759, 1783, and 1548 differentially
hypermethylated CpG islands (DMCGIs) in colorectal, lung, and pancreatic cancer, respectively
(Figure 19d-f). Unsupervised hierarchical clustering of the top 100 hypermethylated CpG islands
ranked by p-value well distinguished cancer patients from non-cancer individuals by dividing these
groups into two clusters (Figure 20). Principal component analysis (PCA) using the top 1000
DMCGIs revealed partitioning of cancer patients from the non-cancer controls (Figure 21). In the
PCA plots, non-cancer samples clustered tightly together, while cancer samples were not clustered,
which may be attributed to tumor heterogeneity. These combined findings suggest that cfMBDseq can reliably identify DMCGIs between the plasma cfDNA of cancer patients and non-cancer
controls.
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3.3.3 Overlap between tissue-derived and cfDNA-derived DMCGIs
To explore whether the DMCGIs detected by cfMBD-seq were originated from tumor tissues, we
acquired Infinium HumanMethylation450 BeadChip (HM450K) data of primary tumors and
matched adjacent normal tissues from the same patients, including colon adenocarcinoma (COAD,
35 pairs), lung adenocarcinoma (LUAD, 21 pairs), and pancreatic adenocarcinoma (PAAD, 10
pairs) from The Cancer Genome Atlas (TCGA) (Figure 22a). We identified 21274, 7635, and
7458 hypermethylated differentially methylated CpG sites (DMCs) (Mean of Dbeta value >0.2,
BH-FDR<0.1, F-test) between primary tumors and matched normal tissues of COAD, LUAD, and
PADD, respectively (Figure 22b-d). To make HM450K results comparable to cfMBD-seq, we
excluded the DMCs that were not annotated to CpG islands and kept the remaining 94.05%,
84.44%, and 90.73% of DMCs in the three cancer types. After further removal of duplicated CpG
islands, we obtained 4630, 2588, 2478 unique DMCGIs for COAD, LUAD, and PAAD,
respectively. As non-tumor-derived cfDNA is mostly released from peripheral blood mononuclear
cells (PBMCs), we conducted an analysis to determine whether the DMCGIs identified by cfMBDseq were not derived from clonal hematopoiesis differences between cases and controls. For this
purpose, we performed similar differential methylation analyses between HM450K data of
primary tumors and cancer-free individuals’ PBMCs (N=61 from Gene Expression Omnibus
(GEO), non-smoker controls in GSE53045) and identified a set of DMCs for each cancer type
(Figure 22e-g). After annotation and exclusion of DMCs, we obtained 7838, 4906, and 5613
unique DMCGIs for COAD, LUAD, and PAAD, respectively. Intersection analyses of three sets
of DMCGIs showed that 84.5% of colorectal (1486/1759), 52.7% of lung (939/1783), and 57.9%
of pancreatic (896/1548) cancer DMCGIs detected by cfMBD-seq overlapped with not only
DMCGIs between primary tumor and adjacent normal tissue, but also DMCGIs between primary
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tumor and PBMCs (Figure 22h). These findings suggest that plasma derived DMCGIs detected
by cfMBD-seq were mainly driven by tumor-specific DNA methylation patterns rather than by
background noise of cell composition in the tumor microenvironment.
3.3.4 Differentially methylated CpG islands for lung cancer detection
Since most HM450K data are originated from early-stage cancer tumor tissue samples, we
hypothesized that the identified overlapping DMCGIs can be used for the early cancer detection.
To test this hypothesis, we acquired an additional cohort of 166 plasma samples including 80 lung
cancer patients (N=22 with early-stage disease) and 86 non-cancer individuals from a previous
cfMeDIP-seq study [134] (Figure 23a). t-distributed stochastic neighbor embedding (t-sne) plot
using the 939 overlapping lung cancer DMCGIs identified a clear separation between lung cancer
and non-cancer individuals in the cfMeDIP-seq cohort, and only 5 individuals were misclassified
(Figure 23b). To rigorously evaluate the utility of these overlapping DMCGIs for cancer detection,
we selected the top 300 lung cancer DMCGIs based on their rank on fold change in the cfMBDseq results and carried out a set of machine learning analyses on the cfMeDIP-seq cohort. We
randomly split these samples into balanced training (80%) and testing (20%) sets. To select the
most discriminating markers, we trained a series of case-versus-control binomial generalized linear
models (logistic regression) with least absolute shrinkage and selection operator (LASSO)
regularization using these top features on the training sets. The process was repeated 100 times to
prevent training-set biases. Eventually, we identified 3 DMCGIs (chr1:243646395-243646888,
chr8:99985734-99986983, and chr21:38068194-38073891) that had non-zero coefficients across
all repeats and selected those as cancer classifier. The normalized sequence reads of the 3 DMCGIs
were significantly higher in lung cancer patients than in non-cancer individuals (Figure 23c). To
evaluate the performance of the classifier, we fit the predictive model on the testing dataset and
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used receive operating characteristic (ROC) statistics to calculate area under the ROC curve (AUC)
for evaluation. The results showed that the model can predict lung cancer in the testing set with
high accuracy (AUC=0.949 [0.929-0.982]) (Figure 23d). Using only the 3 DMCGIs for t-sne plot,
all samples were correctly classified (Figure 23e). These results suggest that early cancer detection
is possible when using tissue-specific DMCGIs identified by cfMBD-seq.
3.3.5 Differentially methylated CpG islands for cancer classification
To further investigate the candidate DMCGIs shared between cfDNA and tumor tissue, we
intersected the three sets of selected DMCGIs for colorectal (N=1486), lung (N=939), and
pancreatic (N=896) cancer. We identified a total of 1271 cancer type specific DMCGIs, including
738 for colorectal cancer, 370 for lung cancer, and 163 for pancreatic cancer. Also, a total of 266
DMCGIs were shared by these three cancer types (Figure 24a). To rigorously evaluate the
performance of these cancer-type specific DMCGIs in cancer classification, we acquired an
additional independent TCGA HM450K data cohort including primary tumors for COAD (N=210),
LUAD (N=385), and PAAD (N=162) (Figure 24b). To convert HM450K data to CpG islandsbased beta value, we filtered out CpG sites that weren’t annotated to CpG islands from 485577
HM450K locus and used the remaining 309465 CpG sites for subsequent analysis. Given the
methylation level between neighboring CpG sites are positively correlated, we calculated the mean
beta values of CpG sites annotated to the same CpG island and generated a beta value matrix for
all CpG islands. We then performed similar machine learning analyses on the HM450K cohort
using the top 100 cancer type-specific DMCGIs. The analyses consisted of 4:1 sample partition,
LASSO regularization, and logistic regression modeling. Rather than a case-versus-control model,
here we built a one-versus-all-others model for each cancer type. After 100 repeats of the training
process, we identified 3 colorectal, 16 lung, 6 pancreatic specific DMCGIs (non-zero coefficients)
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as cancer type classifier. Again, we fit the predictive model on the held-out testing set and applied
ROC statistics for evaluation. The results showed great performance in the prediction of cancer
type (median AUC=1 for COAD, 1 for LUAD, and 0.989 for PAAD). Methylation levels of cancer
type specific DMCGIs are higher in its specific cancer type than in other cancer types (Figure
24c). To better visualize the classification performance, we generated t-sne plot using these cancer
type classifiers and observed clear separation by tumor type in the cfMBD-seq plasma cohort
(Figure 24d). This separation was notably reproduced in the HM450K cohort of 757 cancer tissue
and 61 blood cell samples (Figure 24e). These results indicate the robust ability of cfMBD-seq to
recover tumor tissue-derived methylation profiles in cfDNA across a range of cancer types and
enable cancer type classification.
3.3.6 Gene annotation of differentially methylated CpG islands
To gain an understanding of the biological process behind cancer type specific DMCGIs, we linked
these DMCGIs to their associated genes (Table 4). Some DMCGIs were annotated to gene
promoter regions. We found that several genes with promoter CpG island hypermethylation are
implicated in immune response, which is generally downregulated in cancer [233]. For example,
the protein encoded by PTGER4 is a member of the G-protein coupled receptor family that can
activate T-cell factor signaling [234]. We not only identified DMCGIs in gene promoter regions,
but also found DMCGIs in gene bodies and intergenic regions. (Table 4). In contrast to promoter
CpG islands hypermethylation that prevents gene expression, hypermethylation in gene body CpG
islands can enhance gene expression levels [235]. Consistent with our findings, several genes with
gene body hypermethylation were associated with the regulation of developmental processes. For
example, the protein encoded by WNT6 and HOXB8 has been implicated in oncogenesis and in
several developmental processes such as embryogenesis. Overexpression of both WNT6 and
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HOXB8 plays key roles in carcinogenesis [236,237]. These results suggest that cfMBD-seq can
capture tumor relevant biological signals in the plasma cfDNA methylome. Taken together, our
results indicate that DMCGIs in cfDNA are useful in cancer detection and classification,
suggesting that tumor-derived epigenomic signals are retained in the cfDNA methylome profiled
by cfMBD-seq.
3.4 Discussion
Blood-based assays that can identify the tissue of origin associated with cfDNA fragments could
be instrumental in detecting and classifying malignancies based on histological subtypes. In this
study, we highlight the potential of hypermethylated CpG islands in cancer detection and
classification. Generally, sequencing data from methylation enrichment-based methods are
analyzed by comparing the relative abundance of captured fragments. The genome is divided into
non-overlapping adjacent genomic windows of a specified width and the number of sequencing
read counts is called for each window. Taking 300 bp window as an example, there will be more
than 10 million genomic regions which requires a significant amount of computing memory. In
this study, instead of genomic windows, we called read counts according to CpG annotation
features. This is because MBD methylation enrichment has bias toward hypermethylation on high
CpG density regions [140]. We found that 42.16% of the sequence reads in this study were mapped
to CpG islands, and that 91.46% of the reads were mapped to the extended CpG islands, which
account for only a small fraction of the human genome (Figure 18). Therefore, by excluding the
large fraction of low value inter CpG regions, the computational efficiency was significantly
enhanced. Additionally, well established RNA-seq data analysis packages such as DESeq2 can be
directly applied to the CpG features read count matrix. Together, this CpG island-centered strategy
is a preferred data analysis method for cfMBD-seq.
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Differential methylation analysis based on a negative binomial model of CpG island read counts
identified overwhelming differentially hypermethylated CpG islands (Figure 19). This is
consistent with the fact that the tumor methylome is characterized by DNA methylation alterations
with CpG islands-specific hypermethylation. Unlike genomic DNA from primary tumor tissue that
can perfectly discriminate from non-cancer specimens, cfDNA in blood has much lower tumorderived signal and much higher confounding signals from normal cells. Additionally, preanalytical factors such as plasma collection and cfDNA library preparation can also affect the
identification of methylation signatures. These factors may partially explain why both clustering
and principal component analysis didn’t perfectly segregate cancer and non-cancer specimens
(Figure 21). In this study, confounding factors such as age and gender were not well matched
between the cases and controls, which may result in false positive DMCGIs. To assess whether
the DMCGIs identified by cfMBD-seq represented tumor-derived DNA methylation changes, we
compared our findings against the HM450K primary tumor tissue data. We first identified a set of
DMCGIs between paired primary tumor tissues and adjacent normal tissues. Since non-tumorderived cfDNA released from blood cells can also lead to false positive results, we then identified
a set of DMCGIs between primary tumor tissues and non-cancer PBMCs to deconvolute the clonal
hematopoiesis effect. In our intersection analysis, the majority of the DMCGIs identified in plasma
using cfMBD-seq were consistent with tumor tissue-derived DMCGIs across all analyzed cancer
types (Figure 22h).
The main limitation of this study is the small sample size which prevented us from building
prediction models using cfMBD-seq dataset. Instead, we selected to use the cfMeDIP-seq and
HM450K datasets for predictive modeling. In the LASSO regularized logistic regression analysis
using overlapping lung cancer DMCGIs in cfMeDIP-seq dataset, the model was able to
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discriminate lung cancer patients and non-cancer controls in the testing set with high accuracy
(Figure 23d). However, when we tried fitting the model to our cfMBD-seq dataset for validation
purpose, the prediction performance was relatively poor (data not shown). Although the
methylation capture principle and data analysis pipelines of these two technologies are highly
similar, the capture efficiencies on fragments with different CpG density are different. cfMeDIPseq preferentially enriches methylated regions with a modest CpG density, while cfMBD-seq
captures a broad range of CpG densities and identifies a larger proportion of CpG islands [101].
These differences may explain the inferior performance of the classifier in our study cohort.
Additionally, it is important to note that HM450K and cfMBD-seq are completely different
technological platforms. Unlike bisulfite conversion-based HM450K, cfMBD-seq is an
enrichment-based method that cannot provide the absolute methylation level at each CpG site.
Taking advantage of the fact that the methylation level between neighboring CpG sites is positively
correlated, we transformed the CpG sites beta value matrix into a CpG islands beta value matrix.
This transformation not only mitigates the disadvantage that HM450K has poor coverage of all
CpG sites, but also makes HM450K data comparable with cfMBD-seq DMCGIs. However, since
HM450K data are derived from tumor tissue genomic DNA, cancer type classifiers identified from
the predictive models cannot be directly applied for cancer classification on plasma cfDNA-based
methylation data. Future studies with larger patient cohorts are needed to validate our findings.
The potential clinical application of cfMBD-seq is worth discussing. Currently, PCR-based assays
such as Epi proColon have been approved by FDA for clinical detection of cancer. However, PCRbased assays are restricted by their low throughput nature and thus is only suitable for the detection
of a specific cancer type. On the other hand, sequencing-based assays are more feasible for pancancer screening. GRAIL takes advantages of targeted bisulfite sequencing by combining

78

methylation signatures of different cancer types and achieves high accuracy in multi-cancer early
detection. Adela is a recently established company that is focused on the detection of cancer by
means of cfMeDIP-seq, another enrichment-based cfDNA methylation profiling method. Adela
debuts with $60 million in Series A financing and is ready to translate to the clinic. The success of
Adela gives promise to cfMBD-seq since it outperforms cfMeDIP-seq in many aspects. cfMBDseq is capable of efficiently capturing and preferentially targeting the methylated CGIs from the
entire methylome using ultra-low input of plasma cfDNA. Unlike targeted bisulfite sequencing,
this enrichment-based profiling method shows robust cancer detection and classification
performance without the need of complicated primer and probe design procedures for the bisulfiteconverted sites. For the detection of a specific cancer type, although cfMBD-seq is cost-efficient
among sequencing-based assays, it is still less competitive in price compared to PCR-based assays.
Nonetheless, for a minimally invasive early cancer detection test applied in the general populations,
pan-cancer screening is preferred. Overall, cfMBD-seq has a promising future in translation to
clinic, but reliable classifiers for more cancer types remain to be identified.
In this proof of principle study, we provide important insights into the possible future clinical
applications of cfMBD-seq. Highlights of the study include: 1) cfMBD-seq enables the
identification of cancer-associated DMCGIs from plasma cfDNA in cancer patients; 2) the
identified DMCGIs are mainly driven by tumor-specific DNA methylation patterns and
demonstrate promise for future studies using this technology for cancer detection and classification;
3) the most discriminating DMCGIs selected by our prediction models are associated with
important biological processes that are contribute to carcinogenesis. In summary, cfMBD-seq is a
non-invasive, cost-effective, bisulfite-free, and sensitive methylation profiling method for
capturing of hypermethylated CpG islands in cfDNA. This study demonstrates potential clinical
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feasibility of cfMBD-seq. The current results provide considerably strong justification for future
biomarker discovery and validation in large-scale patient populations. Our findings underscore the
utility of differentially hypermethylated CpG islands in cfDNA for accurate cancer detection and
multi-cancer classification.
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Figure 16. Workflow chart of data generation and analysis
BH-FDR, Benjamini-Hochberg false discovery rate; DMRs, differentially methylated regions;
DMCGIs, differentially methylated CpG islands; LASSO, least absolute shrinkage and selection
operator.
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Figure 17. Quality controls of cfMBD-seq
a. cfDNA concentration (ng cfDNA per ml plasma) from colorectal cancer (N=13), lung cancer
(N=12), pancreatic cancer (N=12) patients, and non-cancer controls (N=16). b. Specificity of MBD
methylation capture reaction across different groups (i.e., Healthy, non-cancer individuals;
Colorectal, colorectal cancer patients; Lung, lung cancer patients; Pancreas, pancreatic cancer
patients) calculated using qPCR Ct value of meth-ylated and unmethylated spiked-in A. thaliana
DNA. c. Total sequence reads and high-quality sequence reads across different groups. d.
Percentage of sequence reads that doesn’t contain any CpG tandem across different groups. e.
Ratio of average non-CpG coverage to average CpG coverage across different groups. Non-CpG
coverage is defined as the average coverage of fragments without any CpG tandem. CpG coverage
is defined as the average coverage of fragments with no less than one CpG tandem. f. CpG density
at peak across different groups. CpG density is defined as number of CpG tandems per fragment.
Peak is defined as fragments with highest coverage.
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Figure 18. Quality controls of CpG islands-centered enrichment
a. Percentage of transcripts per million (TPM) normalized reads on CpG islands across different
groups. b. Percentage of TPM normalized reads on CpG islands/shores/shelves across different
groups. For all box plots, the extremes of the boxes represent the upper and lower quartiles, and
the center lines define the median. Whiskers indicate 1.5x interquartile range. c. Percentage of
sequencing coverage across different CpG annotation features (i.e., CpG islands, CpG shores, CpG
shelves, and inter CpG regions) for all samples. d. Percentage of different CpG annotation features
in base pair size in hg19 human genome. For all box plots, the extremes of the boxes represent the
upper and lower quartiles, and the center lines define the median. Whiskers indicate 1.5x
interquartile range.
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Figure 19. Differentially methylated regions between cases and controls
a-c. Volcano plots of differentially methylated regions (DMRs) at extended CpG islands (CGI)
(i.e., CpG islands, CpG shores, and CpG shelves) between colorectal cancer (N=13) (a) / lung
cancer patients (N=12) (b) pancreatic cancer (N=12) (c) and non-cancer controls (N=16). Black
dots indicate non-significant regions. Blue and red dots indicate statistical significance at
Benjamini-Hochberg false discovery rate (FDR) < 0.1 (negative binomial model, Wald test). Red
dots also indicate regions with absolute fold change (FC) >2. d-f. Volcano plots of DMRs at CpG
islands between colorectal cancer (d) / lung cancer patients (e) pancreatic cancer (f) patients and noncancer controls.
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Figure 20. Heatmap of cfMBD-seq DMRs between cases and controls
a-c. Unsupervised hierarchical clustering (z scores normalization of DESeq2 normalized counts, Euclidean
distance, and Ward Clustering) of the top 100 differentially hypermethylated CpG islands between
colorectal cancer (a) / lung cancer (b) / pancreatic cancer (c) patients and non-cancer controls. Dendrogram
shows separation by sample type (case or control).
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Figure 21. Principal component analysis of DMRs detected by cfMBD-seq
a-c. Principal component analysis using DESeq2 normalized counts of top 1,000 differentially
hypermethylated CpG islands between colorectal cancer (a) / lung cancer (b) / pancreatic cancer (c)
patients and non-cancer controls. The 95% confidence ellipses for the case and control are
displayed. d-f. Proportion of variance explained by each principal component.
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Figure 22. HM450K DMCs between primary tumors and normal tissues / blood cells
a. Pathology stage (according to the AJCC/UICC 7th Edition) in the HM450K cohort including N=66 paired primary tumors and adjacent
normal tissues, and N=61 non-cancer peripheral blood mononuclear cells (PBMCs). Early-stage consists of stage I and II. Late-stage
consists of stage III and IV. b-d. Volcano plots of DMCs between primary tumors and adjacent normal tissues for COAD (N=35) (b)
LUAD (N=21) (c) or PAAD (N=10) (d) from HM450K data. e-g. Volcano plots of DMCs between primary tumors and PBMCs for
COAD (e), LUAD (N=21) (f), or PAAD (g). For all volcano plots, black dots indicate non-significant regions. Blue and red dots indicate
regions significant at Benjamini-Hochberg false discovery rate (BH-FDR) < 0.1 (F-test). Red dots also indicate regions with mean of
beta value >0.2. h. Venn diagram showing the number of overlapping regions between plasma-derived differentially methylated CpG
islands (DMCGIs) from cfMBD-seq and tissues-derived DMCGIs from HM450K in three cancer types (i.e., C, colorectal cancer; L,
lung cancer; P, pancreatic cancer.
87

Figure 23. Differentially methylated CpG islands in lung cancer detection
a. Pathology stage (according to the AJCC/UICC 7th Edition) in the cfMeDIP-seq cohort. Earlystage consists of stage I and II. Late-stage consists of stage III and IV. b. t-distributed stochastic
neighbor embedding (t-sne) plot using all 939 lung DMCGIs that are overlapped between cfMBDseq and HM450K data for the entire cfMeDIP-seq plasma samples (N=166). c. Predictive
modeling using LASSO regularized logistic regression case-versus-control models on cfMeDIPseq cohort including lung cancer patients (N=80) and non-cancer controls (N=86). ROC curve for
20% of held-out testing set is shown. AUC values represent median and interquartile range for 100
repeats of the model. d. t-sne plot using the top 3 lung cancer specific DMCGIs identified from
training set for plasma samples of the entire cfMeDIP-seq cohort. e. Log transformed transcripts
per kilobase million (TPM) sequence reads of the classifier from the cfMeDIP-seq training set.
The extremes of the boxes define the upper and lower quartiles, and the center lines define the
median. Whiskers indicate 1.5x interquartile range.
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Figure 24. Differentially methylated CpG islands in cancer classification
a. Venn diagram showing the number of tissue specific DMCGIs for each cancer type and the number of DMCGIs that are common in
all three cancer types. b. Pathology stage (according to the AJCC/UICC 7th Edition) in the TCGA HM450K cohort of different tumor
(N=757). Early-stage consists of stage I and II. Late-stage consists of stage III and IV. c. Predictive modeling using LASSO regularized
logistic regression one-versus-all-others models on the HM450K cohort including 210 colon adenocarcinoma (COAD) samples, 385
lung adenocarcinoma (LUAD) samples, and 162 pan-creatic adenocarcinoma (PAAD) samples. Area under the curve (AUC) values are
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Figure 24. (Continued) calculated from 20% of held-out testing set. Boxplots represent median and interquartile range for 100 repeats
of the models. d & e. t-sne plot using cancer type specific classifiers identified from training set for the entire cfMBD-seq plasma cohort
(N=53) (d) and HM450K tissue cohort (N=757 primary tumor and N=61 non-cancer PBMCs) (e). f. Beta value of cancer type specific
classifiers (Colorectal cancer specific: chr2:29337984-29338909; Lung cancer specific: chr7:27265159-27265493; Pancreatic cancer
specific: chr10:11059443-11060524) across COAD, LUAD, PAAD, and PBMC samples. The extremes of the boxes define the upper
and lower quartiles, and the center lines define the median. Whiskers indicate 1.5x interquartile range.
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Table 3 Clinical demographic characteristics of patients in the cfMBD-seq cohort
Type

Age

Non-cancer

Colorectal cancer

Lung cancer

Pancreatic cancer

Mean

49.38

67.88

58.33

61.25

Median

52.5

72.5

57.5

62.5

Range

42.5-52.5

47.5-82.5

42.5-67.5

42.5-67.5

Male

5

11

9

8

Female

11

2

3

4

Caucasian

15

11

12

11

0

2

0

1

Asian

1

0

0

0

I-II

\

0

0

0

III-IV

\

13

12

12

Adenocarcinoma

\

11

9

10

Others

\

2

3

2

Gender

African
Race
American

Pathological Stage

Histology
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Table 4. Annotation of the most discriminating cancer type specific DMCGIs
CpG islands
Colorectal cancer
chr2:29337984-29338909
chr2:100937780-100939059
chr6:125283125-125284389
Lung cancer
chr2:66672432-66673636
chr2:71503548-71504233
chr2:219736133-219736592
chr4:140655963-140657135
chr4:174427892-174428192
chr5:40679503-40682081
chr7:27265159-27265493
chr7:65037625-65037864
chr8:124172801-124173541
chr9:96108467-96108992
chr12:54408427-54408713
chr12:58021295-58022037
chr13:28549840-28550246
chr17:46691521-46692097
chr17:59539363-59539834
chr17:70112825-70114271
Pancreatic cancer
chr1:44883137-44884272
chr1:50798668-50799536
chr5:92939796-92940216
chr10:11059443-11060524
chr11:20177609-20178824
chr12:114881650-114881937

Size (bp)

Gene

Location

926
1280
1265

CLIP4
LONRF2
RNF217

Promoter
Promoter
Promoter

1205
686
460
1173
301
2579
335
240
741
526
287
743
407
577
472
1447

MEIS1
ZNF638
WNT6
MGST2
\
PTGER4
\
\
\
C9orf129
\
B4GALNT1
\
HOXB8
TBX4
SOX9

Gene body
Promoter
Gene body
Gene body
Intergenic
Promoter
Intergenic
Intergenic
Intergenic
Promoter
Intergenic
Gene body
Intergenic
Gene body
Gene body
Promoter

1136
869
421
1082
1216
288

RNF220
\
\
CELF2
DBX1
\

Gene body
Intergenic
Intergenic
Promoter
Gene body
Intergenic
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